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Over the past decade, work from our laboratory has demonstrated the
potential of targeted nanoformulated antiretroviral therapy (nanoART) to produce
sustained high plasma and tissue drug concentrations for weeks following a
single intramuscular (IM) administration that can suppress ongoing viral
replication and mitigate dose associated viral resistance. While progress has
occurred towards developing long-acting nanoformulations for protease and
nonnucleoside

reverse

transcriptase

(RT)

inhibitors,

development

of

nanoformulations of hydrophilic nucleoside RT inhibitor drugs have remained
elusive. Abacavir (ABC); a hydrophilic molecule exhibited limited utilities to
develop into long-acting nanoformulation platform. Furthermore, inefficient
conversion of ABC to its biological active metabolites; carbovir triphosphate
jeopardizes its therapeutic index.

Thus, improving bioavailability and the

therapeutic index of the ABC is urgently needed. To this end, a phosphoramidate
prodrug of ABC (PABC), and a myristoylated prdrug of ABC (MABC) was
synthesized to improve the therapeutic index of its native hydrophilic counterpart.
The notion of PABC synthesis was to increase intracellular nucleoside 5’O- triphosphate levels by bypassing rate-limiting monophosphorylation of the
parent drug. We reasoned that long-acting PABC nanoformulations could

improve ABC’s Pharmacokinetic (PK) and pharmacodynamics (PD). Herein,
PABC was successfully synthesized and characterized by 1H-NMR and FTIR
spectroscopy.

PABC was incorporated into a PLGA-lipid nanoformulation. In

vitro and in vivo viral efficacy of PABC and PABC encased nanoformulation were
evaluated in human monocytes derived macrophages (MDM) and Hu-PBL
reconstituted NSG mice respectively. Concomitantly, a platform was constructed
to convert the hydrophilic ABC into a hydrophobic derivative through
esterification at 5’-OH position of ABC (MABC). MABC was loaded with high
concentration into a polymer and decorated with appropriate targeting ligands for
improvement in biodistribution, half-life and antiretroviral efficacy. Antiretroviral
activity, uptake, retention and cellular trafficking of both the pro-drug and MABC
encased in poloxamer nanoformulations were assessed in MDM. Drug PK was
evaluated over 14 days for ABC and nanoformulated MABC after intramuscular
injection in Balb/c mice.
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CHAPTER 1
OVERVIEW AND STATEMENT OF THE
PROBLEMS
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1.1 THE HUMAN IMMUNODEFICIENCY VIRUS (HIV): STRUCTURE AND LIFE
CYCLE
HIV is a class of viruses belongs to a group called retroviruses, and a
subclass of retroviruses called as lentiviruses. A long hiatus between initial
infection and the onset of AIDS occurs following HIV infection. Like all viruses,
HIV survives and reproduces inside living cells, hijacking the host cell’s
machinery to replicate. HIV mainly infects the CD4+ T lymphocytes and to a
lesser extent mononuclear phagocytes (MP; monocytes, macrophages, and
dendritic cells) as these cells are also express cell surface CD4, a prerequisite
for HIV to enter. Once infected HIV commandeers the cell, where cells eventually
loses its function [1-3].
The genomics of HIV composed of ribonucleic acid (RNA) molecules,
whereas the genes of most other organisms including humans are composed of
deoxyribonucleic acid (DNA). However, once inside the cell, HIV like other
retroviruses convert their RNA into DNA by using enzyme reverse transcriptase
(RT), followed by its incorporation into the human cell’s genomes. To develop a
delivery system for prevention of HIV, an understanding about the steps involved
in HIV life cycle is crucial (Figure 1.1)[3-5]. There are multiple steps in the life
cycle of HIV as explained below;
1. Binding and Fusion: The first step in the HIV entry process (Figure 1.1) is the
attachment of a viral particle to the CD4 receptor and a co-receptor (either CCR5
or CXCR4) of the host cell. In particular, the gp120 of HIV bind to CD4 receptors,
expressed on the surface of T lymphocytes, monocytes, macrophages and
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dendritic cells. Binding to CD4 induce a conformational changes in the viral
envelope that are necessary for membrane fusion and viral entry. The next step
is the binding of gp120 to co-receptors CCR5 and CXCR4. After the first
conformational change during the binding of gp120 to CD4 cell receptor, the viral
gp120-gp41 glycoprotein complex undergoes further conformational changes,
exposing the N-terminal domain of gp41 and allowing the fusion peptide
sequence to insert into the cellular membrane of the host cell.
2. Reverse Transcription: The fusion stage is followed by the reverse
transcription and integration stages. The reverse transcriptase (RT) enzyme
converts single-stranded HIV RNA into double-stranded HIV DNA through a
process called reverse transcription, so it can be integrated into the host DNA.
3. Integration: The new virus genetic material enters the nucleus of the CD4 cell
and integrates itself into host genetic material with the help of integrase enzyme.
Once the viral DNA has integrated into the host cell’s DNA, the host cell is
infected for the remainder of its life. The integrated viral DNA is now called as a
provirus.
4. Transcription and Translation: The provirus DNA serves as a template for
the creation of new viral RNA via a process known as transcription using the host
cell enzymes. This results in the production of multiple copies of viral RNA. The
newly formed viral RNA moves out of the infected cell’s nucleus. The viral RNA
carries code for the synthesis of viral proteins and enzymes through the
translation process. The code is translated into long chains of amino-acids
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(polypeptide chains), which fold to produce structural proteins such as the viral
envelope and enzymes (reverse transcriptase, integrase, and proteases).
5. Assembly, Budding and Release: The protease enzymes cut the longer HIV
proteins into individual proteins. When these come together with the virus genetic
material, a new virus bud has been assembled. Budding is the final stage of the
HIV virus life cycle. In this stage, the virus pushes itself out of the host cell, taking
with it part of the membrane of the cell. This outer part covers the virus and
contains all of the structures necessary to bind to a new CD4 cell and receptors
and begin the process again. A single infected cell can release many new HIV
particles which move on to infect other cells in various parts of the body, where
the viral life cycle is repeated. The infected cells are eventually destroyed.
1.2 THE HIV PANDEMIC
In 1981, the CDC (USA) began investigation of rare opportunistic
infections among a group of homosexual men. These patients were later
confirmed to be severe immune deficient, and later their disease syndromes
were coined as Acquired immune deficiency syndrome (AIDS) [6, 7]. In 1983, two
independent groups in the United States and France simultaneously investigated
the cause of these infections, and named Human T Lymphotropic Virus (HTLVIII) and Lymphadenopathy Associated Virus (LAV) respectively [8-11]. In addition
to HTLV-III and LAV, a third virus name AIDS-associated Retrovirus (ARV) were
isolated from AIDS patient, later found to be the same virus, and renamed as
Human Immunodeficiency Virus, or HIV [12]. Since the epidemic began in the
early 1980s, more than 75 million people have been infected and more than 30
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million people have died of HIV-related infections. With 2.0 million new infections
and 1.2 million deaths in 2014-2015, AIDS still remains the deadliest epidemic of
our time. According to the recent report of the global AIDS epidemic, there are
approximately 37 million people currently living with HIV/AIDS infections,
corresponding to 0.8% of the total population of adults aged 15-49 years
according to The Joint United Nations Programme on HIV and AIDS (UNAIDS)
statistics[13, 14].
1.3 CLINICAL MANIFESTATIONS
HIV infection is distinguished into three phases; acute syndrome, clinical
latency and clinical AIDS. Figure 1.2 shows a typical progression of the disease
without antiretroviral treatment[15]. Note that CD4+ T cell counts drop rapidly
during acute HIV disease, followed by a more gradual loss during clinical latency.
During the early phase of infection, HIV can be detected followed by decline of
plasma virus level to undetectable, and a phase of “latency” is ensured. The
symptoms of early primary HIV illness, named as acute retroviral syndrome
(ARS) can be seen within first 2-6 weeks. The symptoms are flu-like and nonspecific, and include fatigue, fever, lymphadenopathy, pharyngitis, anorexia,
candidiasis,

splenomegaly,

hepatomegaly,

oral

lesions,

and

macular

erythematous rashes, ulcers of genitourinary system, photophobia, and weight
loss among others. The usual neurological symptoms observed are aseptic
meningitis and headache. Approximately 70% of HIV infected the patients
experienced ARS [16, 17].
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The phase of acute infection is characterized by the active reproduction of
virus and rapid declined in CD4+ T cells count, followed by inversion of CD4 to
CD8 cells ratios. The numbers of HIV in peripheral circulation are in a range of
105 to 106 HIV RNA copies/ ml. The acute HIV infection can be diagnosed by
HIV-1 RNA testing, western blot assay, and by investigating HIV antigen and
antibody using HIV enzyme-linked immunosorbent assay (ELISA).
Followed by initial high viremia peaks, the level of HIV in the blood falls off
to very low to non-detectable, and a phase of "latency" ensured. During the
latency phase, few HIV symptoms are observed in patients, oral, skin,
constitutional complications and an obvious persistent of lymphadenopathy are
typical. Though HIV load is very low, a high turnover of CD4+ T cells and HIV
virion production persist during this phase.

This stage of “latency” can be

prolonged up to an average of 10 years without antiretroviral therapy (ART).
Eventually, the viral load continues to increase and next stage of HIV prognosis
termed ‘symptomatic HIV disease’ incept.
In the late-stage of HIV infection, called Acquired immune deficiency
syndrome (AIDS) viral load continues to increase. CD4+ T lymphocyte cell count
declined to a level less than 200-349 cells/μL in children older than 5 years. At
this stage patient immune system is severely impaired, and patient succumbs to
many opportunistic infections or malignancies like rare cancers (Kaposi's
sarcoma) and other HIV infection manifestations (such as neuropathy) that
eventually lead to death. HIV Patients with AIDS without on antiretroviral therapy
(ART) usually cannot survive more than three years [17-21].
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1.4 ANTIRETROVIRAL THERAPY (ART)
Current regimen for ART includes combination of drugs that restrict HIV
replication by targeting different stages of the viral life cycle. The use of a
combination of antiretroviral drugs (ARVs) delay disease progression and
diminish viral load for an extended period of time that led to profound decreases
in morbidity and mortality rates in AIDS patient as well restricts HIV transmission
from one person to another. A combination of protease inhibitor and nucleoside
reverse transcriptase inhibitors (NRTIs) are the most used ART regimens.
However, development of drug resistance, toxicity and complication associated
with current regimen driving the development of novel antiviral agents that target
HIV life cycle other than protease or reverse transcriptase. HIV entry inhibitors,
viral integrase inhibitor that prevent integration of HIV DNA into the host DNA,
virion maturation inhibitor etc. are currently potential emerging HIV targets for
ART as shown in figure 1.3, The novel targets antiviral agents present new
treatment options that are most likely to be fully effective against multi-drug
resistance virus, and thus may act as synergistic to current other inhibitors[5].
ART is now prescribed for all adults with HIV infection, with an initial
prescription

includes

combination

of

two

NRTIs;

tenofovir

disoproxil

fumarate/emtricitabine or abacavir/lamivudine and a third single or boosted drug,
which should be a boosted protease inhibitor or integrase strand transfer inhibitor
or a nonnucleoside reverse transcriptase inhibitor. Table 1.1 present the general
classification of current ART used alone or in combinations.
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Table 1.1. Classification of Antiretroviral Drugs
Classifications

Ref.

Category: Reverse Transcriptase (RT) Inhibitors

[22-

MOA: RT Inhibitors block a process a process called reverse 24]
transcription, by inhibiting the activity of RT enzyme; transcription of
single-stranded HIV RNA to double-stranded HIV DNA.
Subcategory-1: Nucleoside/nucleotide RT inhibitors (NRTIs)
MOA: NRTIs act by blocking RT enzyme. These drugs competitively to
natural nucleoside analogs get incorporated into HIV DNA, leading to
termination of DNA synthesis.
Drugs:

Abacavir,

Lamivudine,

Tenofovir,

Adefovir,

Emtricitabine,

Zidovudine, Entecavir, Zalcitabine, Didanosine, Festinavir, Stavudine,
Tenofovir

disoproxil

fumarate,

Apricitabine,

Tenofovir

alafenamide

fumarate.
Subcategory-2: Non-nucleoside RT inhibitors (NNRTIs)
MOA: NNRTIs inhibit the reverse transcription by binding to a pocket near
the active site that leads to conformational change of the enzyme.
Drugs:

Doravirine,

Efavirenz,

Etravirine,

Nevirapine,

Delavirdine,

Rilpiverine.
Category: Protease Inhibitors

[25,

9

MOA: Inhibit virus-specific processing of viral Gag and Gag-Pol 26]
polyproteins in HIV infected cells by inhibiting viral protease.
Drugs: Saquinavir, Lopinavir, Atazanavir, Darunavir, Ritonavir, Indinavir,
Nelfinavir, Amprenavir, Fosamprenavir, Tipranavir
Category: Integrase Inhibitors

[27]

MOA: Inhibit the activity of HIV integrase, and thus block the integration of
viral DNA into the DNA of the host cell.
Drugs: Elvitegravir, Raltegravir, Dolutegravir.
Category: Fusion Inhibitors

[28]

MOA: Inhibit the conformational changes required for viral membrane
fusion with the cells, where it binds to the HIV-1 membrane glycoprotein.
This inhibits HIV from entering a cell.
Drugs: Sifuvirtide , Enfuvirtide.
Category: Entry Inhibitors

[28]

MOA: Bind to gp120 receptors on the outer surface of the cell, and thus
interfere with the virus ability to enter into host cell.
Drugs: Maraviroc, Vicriviroc
Category: Maturation Inhibitors

[29,

MOA: Maturation inhibitors blcok the last step in gag processing in which 30]
the viral capsid polyprotein is broke down, thereby inhibiting the
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conversion

of

the

polyprotein

into

the

mature

capsid

protein.

Consequentially, viral particles with a defective core is produced, and thus
of non-infectious in nature.
Drugs: Alpha interferon, Bevirimat, Vivecon.
Category: Capsid Inhibitors

[31]

MOA: Inhibitors of HIV-gag polypeptide assembly. Dismantles assembled
HIV-1 capsid assembly tubes.
Drugs: under investigation
Newer categories under development:
LEDGF-based

inhibitors,

Vpu/tetherin-based

Budding

inhibitors,

inhibitors,

[32]
RNaseH

CA/TRIM5α-based

inhibitors,
inhibitors

Vif/APOBEC3G-based inhibitors.

However, with the advent of current ART regimens, a profound decrease
in morbidity and mortality rates in AIDS patient HIV is possible, but complete
eradication is still a major challenge. The eradication of HIV is hampered by its
ability to stay hidden in restricted anatomical sites and within infected blood cells
to remain as a life-long infectious agent. It is much obvious that hidden virus into
those anatomical reservoirs present a major challenge to combat HIV infection.
Hence long-term use of ART regimens, which otherwise have adverse impacts,
will continue at least in near future.
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1.5 HIV RESERVOIR; A CHALLENGE IN HIV ERADICATION
Combination antiretroviral therapy (cART) has substantially reduced the
morbidity and mortality rate in HIV patient, but patient must adhere to therapy for
lifelong, and virus rapidly rebounds if therapy is discontinued [21, 33]. The major
reason outlined the rebound of virus, and thus complete eradication is
persistence of HIV reservoirs throughout the anatomical sites even patient is on
ART [34, 35]. Therefore combat with latent virus in those reservoirs remains a
formidable obstacle in complete eradication of HIV. This section focuses on
recent advancement in understanding of where virus hides and established
latency that would insight our efforts on designing formulation strategies that
penetrate deep into these sites, and established a step toward the elimination of
latent virus. The hide out of latent virus in a HIV patient is classified into two
categories; 1) cellular reservoirs[36] and 2) anatomical reservoirs [37].
1.5.1. Cellular Reservoir
1.5.1.1. Memory T Cells
The HIV infected resting memory CD4+ T cells and lymphoid tissue of HIV
patients on cART was reported to be the source of persistence latency in late
90’s. More recently, both transitional memory CD4+ T cells (CD45RA-CCR7CD27+) and central memory (CD45RA-CCR7+CD27+) have been reported as
the major infected cells in HIV-infected patients receiving cART. Latency has also
been identified in other T-cell subsets and other cell types are important to
investigation, by which they may differ in mechanism of HIV persistence[36].
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1.5.1.2 Naive T Cells
Persistence of latency in naive CD4+ T cells in HIV patients on cART has
been reported, although the intensity of infection compared with memory CD4+ T
cells is approximately 1–2 logs less. The concentration of HIV DNA in CD31+
naive CD4+ T cells (enriched for recent thymic emigrants), and CD31- naive
CD4+ T cells (naïve cells that have undergone homeostatic proliferation) was
found to be similar prior to and after cART. However, following cART the
absolute number of infected naive CD4+ T cells was increased; suggesting that
the reservoir of infected naive T cells may expand over time[36].
1.5.1.3 Hematopoietic Progenitor Cells
Recently, it has been evident that HIV can be persisting latently in CD34+
hematopoietic progenitor cells (HPCs).

Integrated HIV DNA was detected in

CD34+ HPCs from 40% of patients on suppressive cART. Although, in vitro
replication of HIV in HPCs showed to be cytotoxic, persistence of latent HIV
could be established in these cells. Further detailed investigation are requires to
understand how latency persist in these cells, whether these cells harbor
infectious virus, and whether these cells could be a source of rebound virus when
patients discontinued cART[36].
1.5.1.4 Astrocytes
HIV infection of primary astrocytes and In vitro astrocyte cell lines results
in integration but marginal virus replication that infers latent infection. Astrocytes
isolated from the HIV infected patients exhibits the presence of integrated HIV
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DNA, which linked to the HIV-associated dementia. However, such findings are
from the viremic patients, further investigations on suppressive cART patient are
require[36].
1.5.1.5 Monocyte-Macrophages
A number of factors lead to MP cell lineage of monocyte-macrophage as
potential HIV-1 reservoirs. Monocytes circulate peripherally for up to three days
before differentiate to macrophage. Viral replication in to these cells is more
persistent in nature which contributes to the low-level virus production lasting lifespan of cells. Limited expression of viral protein enables these cells to evade the
immune system. However, the latency pool in monocytes-macrophages cells
lineage is comparatively smaller than T-cells pools. Less than 1% of monocytes
estimated to have HIV-1 proviral DNA, while about 50 in millions lymph nodes
macrophages are found infected. The lesser extent of infection is results of low
CD4 surface expression which impair virus binding efficacy, but also to
restrictions in nuclear import and reverse transcription leading to limited infection.
The monocyte-macrophage HIV-1 reservoir reportedly exhibits resistance to
protease inhibitors (PIs). The overexpression of P-glycoprotein transporters in
these cells lineages suggested being the mechanism of resistance that limits the
bioavailability of PIs[36].
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1.5.2 Anatomical Reservoir
1.5.2.1 Gastrointestinal Tract (GIT)
The GIT is prominent reservoir for latent HIV infected cells in suppressive
cART patient. The concentration of integrated DNA in GIT is reported to be five
to ten times higher than in peripheral blood mononuclear cells. Within GIT, the
distribution of HIV-DNA and RNA differ, with rectum having highest concentration
of HIV DNA, and ileium with highest concentration of HIV RNA. A nonsignificant
decrease in HIV RNA, suggesting ongoing HIV replication was observed in
patient on suppressive cART [34, 37].
1.5.2.2 Lymphoid Tissue
HIV infected CD+ T cells carrying integrated HIV DNA through the
systemic and lymphatic circulation constitutes lymphoid tissue an important,
although less studied reservoir in HIV patient receiving suppressive cART.
Moreover, the follicular dendritic cells or other myeloid cells home to germinal
center may provide a stable source of latent virus. The interaction of dendritic
cells to T-cells may contribute to the ongoing latency in resting T-cells [34, 37].
1.5.2.3 Genitourinary Tract
The presence of HIV RNA is detected in genital secretion in 54% of
women and in semen in 8 to 10% of men receiving cART, indicating a reservoir
in genital tract, although the source remains unclear. In the CNS, the limited
bioavailability of cART to genitourinary tract makes it susceptible for ongoing
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latency in these site. Moreover, the blood-testis barrier in male genitourinary
tract, specifically restrict the entry of immune cells. In vitro study revealed that
human testicular tissue can support HIV reproduction, but whether HIV- infected
cells persist in these sites remain unclear[34, 37].
1.5.2.4 Central Nervous System (CNS)
The CNS, with its long-lived unique cells, is identified as persistent
reservoir for latent HIV in patient on cART. Since, the blood-brain barrier restrict
the entry of cART and HIV-specific immune cells to the CNS, the CNS cells are
more susceptible to HIV reservoir then peripheral cells and sites. Latently
infected astrocytes and monocytes are potential source of HIV reservoir in brain.
A low level of HIV RNA also has been detected in cerebrospinal fluid in about
10% of patients receiving cART. Further detailed investigation in HIV reservoir in
CNS in patient on cART is desired [34, 37].
1.6 EFFORTS TOWARDS THE ERADICATION OF HIV-1 RESERVOIRS
Although the introduction of highly active antiretroviral therapy (HAART)
has considerably improve the quality of life and life-expectancy of HIV patients,
complete eradication of virus, is so far, not possible. Several strategies have
been proposed, and under development to eradicate HIV completely.
Considerably, structured treatment interruption (SIT) and immune activation that
may boost the intensification of HAART are of particular interest[38].
SIT follows hypothesis that HIV specific immunity will be boosted by
HAART interruption, through controlled exposure of virus over a predefined short
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periods of time. It was expected that following several interruption, immune
response will be adapted enough to control virus replication even in absence of
HAART. However, despite intensive research and knowledge gained over SIT,
the clinical outcome in terms of decreasing the intensity of lately infected cells
population failed, in fact it has been associated with worsening the clinical
outcome then of patients on HAART alone [39, 40].
Immune activation therapy was designed to eradicate resting CD4+ T cells
out of latency, and may be in combination with HAART boost the protection of
uninfected cells. Several CD4+ T cells activating agents have been investigated
in clinical studies including OKT-3, IL-2, and valproic acid. Didanosine and
enfuvirtide in combination with Hydroxyurea was reported to boost HAART.
However, in all case, evidence existed for rebound of virus upon discontinuation
of therapy. Additionally, toxicity associated with HAART intensification limits the
implementing, and thus clinical outcome[36].
The advancement of technology such as RNA interference that would
silence the viral promoters within cells pool in HIV-1 reservoir would overcome
the necessity for viral gene expression as well circumvent the toxicity associated
with HAART intensification and immune cells activation[41]. Although these
strategies towards HIV eradication are worth pursuit, their clinical efficacy is
severely compromised by the specificity and delivery. The lack of specificity, in
particular, delivery of antiviral agent to the virus hideout would obviously
emphasize the need for the new drug delivery approaches to achieve HIV-1
eradication. One of such interested drug delivery technology is utilizing body own
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immunocytes. To this context, immunocytes, in particular mononuclear
phagocytes (monocytes, macrophages, and dendritic cells) as drug delivery
vehicle offer several advantages over conventional drug delivery [42].
1.6.1 Macrophage-Mediated Drug Delivery: A Promising Approach In Latent
Virus Eradication
As discussed earlier (section 1.5.1.5), the long-lived macrophages make a
perfect hideout for HIV for long period of time, thus constituting HIV reservoirs
and posing a major challenge to complete virus eradication from HIV-infected
patient. Mature HIV-1 can be stored within intracellular vesicles of macrophage
for weeks (33). Evidences have suggested a key role of macrophages in the
failure of the immune system to achieve HIV clearance within the acute and
chronic

phases

of

infection.

Therefore,

targeting

drug

delivery

to

monocytes/macrophages in particular, not only eliminates HIV but an opportunity
to use the very mechanism(s) the virus uses to escape destruction[43].
Additionally, using macrophages as drug delivery vehicle offers several
advantages over conventional drug administration regimens. These include
predefined drug delivery to specific disease sites, in particular HIV anatomical
hideouts; prolonged the biological half-life, thus PK of cART; controlled drug
release; and minimize drug cytoxicity and immunogenicity. In addition,
macrophage-mediated delivery can act as “Trojan horses” carrying hidden
therapeutic pay-loads while transporting across formidable barriers; such as, the
blood brain barriers [42].
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Despite such advantages, clinical outcome for such system is jeopardized
for several reasons. First, a poor drug loading into macrophage cells makes it
inefficient delivery vehicle. Second, entrapped therapeutic agents

may

degrade/disintegrate within cellular compartments, lysosomal compartment in
particular. Third, the macrophage should ensure loaded drug to stay within
cellular vesicles till the cell reach to the predefined site of action or disease site,
thus loaded payloads should not be released prematurely. Fourth, the cell
carriers should transport to the disease site in therapeutically efficient quantities.
In particular, transmigrating capability of macrophages should not be
compromised during drug entrapment. Finally, the drug formulations must be
safe enough to ensure all biological function of cells [42].
Many of these hurdle can be overcome by pre-packing the drug load/s into
polymeric matrix that ensure a safest way to load high drug content that not only
preserve the drug loads within cellular organelles but also sustain the release for
an extended period of time [44]. Incorporation of drugs into protective polymeric
nanoparticulate system is of particular interest by overcoming specified
challenges.
1.6.2 Design Consideration of Cell-Mediated Drug Delivery Construct
The concept of cell-mediated drug delivery is very promising and under
development. Specific considerations must be addressed ahead of time while
constructing cell-carriers, for example, adequate drug loading capacity, controlled
drug release at site of action, preservation of drug inside polymeric matrix and
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endosomal vesicles, efficient homing of these drug carrying cells to site of
interest and safety are some of important issues[42].
1.6.2.1 Drug loading into the macrophages
Nanocarriers commonly have a polymeric matrix core that permits drug
entrapment, while outer polymeric layer define the nanocareers aqueous
dispersion, systemic circulation time. The surface coating of these drug carriers
have a notable impact on their interaction with macrophages that affects the
cellular loading. In general, the macrophage uptake of charged nanoparticles are
rapid and higher compared to neutral nanocarriers. Positively charged
nanoparticles reported to accumulate in macrophages to a greater extent than
negatively charged particles. The mechanism lies in the fact that positivelycharged nanocarriers likely to adsorb more on negatively-charged cell membrane
of macrophage, derived by electrostatic attraction[45]. Moreover, the cell
entrapment of these nanocarriers can be facilitated through engineering the outer
surface using specific receptor targeting moiety that recognize specific receptors
expressed on the cell surface, in particular, Fc, complement, mannose and folic
acid receptors are among some of notable targeted receptors[46].
The shape and size of nanocarriers have a significant impact upon cellular
uptake. It has been reported that attachment of particles of different geometry to
the macrophages surfaces are strongly dependent on shape and size. Particles
that possess longest dimension, in the range of 2–3 µm exhibited superior
attachment. The mechanism lie in the facts the macrophage evolved to engulf
maximum number of bacteria, most of which exist in same size range.
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Furthermore, the uptake of particles with the size about 1μm was significantly
higher than particle with the size of about 500 nm[45]. Recently, the effects of
shape on cellular uptake were investigated in alveolar rat macrophages using
more than 20 shapes of

polystyrene-based particles. It has been revealed that

shape of particles at the point of contact; where it attaches to macrophage play
an important role in phagocytosis. For example, the attachment of sharper end of
ellipse with macrophage would facilitate particles internalization within minutes.
In contrast, macrophage attached to the particle on dull end side would limit
phagocytosis [47].
1.6.2.2 Drug preservation into the macrophages
The investigation of intracellular trafficking of the nanocarriers among
other factors is of key important in defining the fate of drug encased nanocarriers
once engulfed by macrophages. In particular, the drug loaded cargo need to bypass the lysosomes in order to avoid drug degradation within acidic cellular
compartments [43]. In this context, the surface charge of nanocarriers is of key
importance in defining the intracellular fate. For example, a diminished
phagosomal acidification was observed with cationic polyamine coated
nanoparticles compared with anionic protein coated nanoparticles. Therefore, the
cationic nanoparticles sought to protect the drug from lysosomal degradation[48].
In a recent study, it revealed that encapsulation of catalase into the positively
charged block copolymers (PEI-PEG and PL-PEG) leads to improve stability of
enzyme in macrophage. In contrast, the loading of enzyme into negatively
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charged

polyion

complex

resulted

in

degradation

of

enzyme

within

macrophages[49].
The intracellular drug degradation can be circumvented by limiting the
carriers being phagocytized, but attached to the cell surface. The “back-pack”
attached to the monocytes/macrophages surface would be hitchhiked to the site
of interest that also improve systemic circulation while preserved encased drug
activity. The avidin coated nanoparticles reported to attach with biotinylated
plasma membrane through the avidin-biotin complex to constitute stable “back
pack”. However, further studies needed to investigate the drug carrying capacity
and immunogenicity of such polymeric “back pack” [50].
1.6.2.3 Drug release from the macrophages
Mechanism underlying the unloading of these nanocarriers at the site of
action remains an active area of investigation. However, a desired controlled
release of cargo has modulated the dose and duration of exposure. To such end,
cellular response to various physical or chemical stimuli can be utilized to trigger
the release. Macrophages, along with mononuclear phagocytic cells, are known
to produce and store the various compound within endosomal vesicle, followed
by their released via exocytosis at disease site. A similar mechanism can be
anticipated for the release of drug and /or drug -loaded carriers, when serve as
drug delivery vehicles. However, further detail investigations are needed to
understand the exact mechanism [42]. The release of drug can be modulated
using external stimuli. For example, by modulating the intracellular concentration
of Ca2+ the drug release can be triggered [51]. Furthermore, the use of mild
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hypothermia was reported to control the release of drug-loaded liposomes from
macrophages in tumor vicinity[52].
1.6.2.4 Drug depot
For cell-mediated drug delivery the numbers of drug carrying cells reach
the site of action of key importance. For example, in case of CNS disorder the
efficacy of cell-carriers is determined by the ability to cross the blood brain barrier
(BBB) to elicit therapeutic end point. For most of cells-carriers the driving force
to the disease site is chemotaxis; a process where most of MP migrate to the
disease site following chemogradient. In many CNS disorder, such as
Parkinson’s and Alzheimer’s disease, meningitis, encephalitis, prion disease and
HIV-associated neurocognitive disorders (HAND) exhibited similar inflammatory
components that recruit MP extensively to the disease periphery. Additionally,
neural stem cells (NSCs) were also reported as drug delivery vehicle for gene
delivery in brain. Indeed, these cells transmigrate more efficiently to the disease
site including neoplastic brain lesions and ischemic lesions. However, the
mechanism to which they transmigrate to the disease area is not clear yet,
although NSCs reported to express a wide variety of receptors that may render
them to respond to many chemotactic signals. In particular, activate microglia
drive NSCs influx to the brain. Therefore, cell-mediated strategies can be
employed to deliver wide range of neurotropic factors that otherwise restricted
due to brain formidable barriers i.e. BBB [42].
In context of cell-mediated drug delivery of anticancer agent, MP are
known to migrate in large number at tumor site, in particular, vascular and

23

hypoxic site, for example in prostate and breast carcinomas. Malignant tumors
have lots more hypoxia due to their unorganized vasculature. The hypoxia driven
cytokines from tumors cells and other physiological stress are the chemotactic
markers that accumulate monocytes and macrophages in tumor vicinity that
facilitate anticancer drug delivery to the cancerous region using these cells as
delivery vehicle[53]. The advantages of cell-carriers in anticancer drug deliver are
to avoid unwanted drug distribution and minimize off-target drug toxicity.
Cells-carriers can be deployed to the disease site by incorporating
magnetic nanoparticles into the therapeutic cargo and fed to the cells carriers
following accumulation at disease site with the aid of external applied magnetic
field. Intravenous injections of RGD-coated magnetic liposomes in albino rats
with brain inflammation exhibited 10-folds brain accumulation under the magnetic
guidance compared to non-magnetic nanoparticles. RGD peptide facilitated
selective

binding

of

these

nanoparticles

to

the

surface

of

monocytes/macrophages that expressed integrin receptors on cellular surface
[54].
1.6.2.5 Safety of cell-mediated drug delivery
One has to be cautious about safety concern while designing cell-carriers
constructs. In particular, the MP migrates to the disease site is usually
accomplished by release of reactive oxygen species (ROS) that cause cell
damage. To this context, many of CNS therapeutic strategies are designed to
limit the monocytes/macrophages infiltration the brain. Therefore, circumventing
cytotoxicities for cell-based drug delivery construct is a prerequisite for
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formulation development of cell-mediated drug delivery system. Nevertheless, in
particular, brain delivery of macrophage-mediated nanoformulated catalase
showed no cytotoxic effects [42]. Furthered detailed investigations are required to
preclude any pitfall of cell-mediated drug delivery for acute and chronic
applications.
1.7 DESIGN CONSIDERATION OF NANOMEDICINE FOR EFFICIENT CELLCARRIERS
One has to be very cautious while choosing right drug packed particulate
while constructing cells-based drug carriers in order to maximize the therapeutic
outcome with least side effect, or that does not have any impact on the integrity
of cellular carriers. The designs of nanocareers need to be optimized in terms of
particles size, shape, and surface chemistry to maximize the cellular uptake, and
thus efficacy of loaded drug/s. all these characteristics are critical for clinical
translation of these carrier system.
1.7.1 Shape, size and surface charge of nanocarriers
Nanoparticles shape and size are the critical parameter which affects the
rate of macrophage uptake. Champion et al revealed that particles of size 2–3
μm in diameter exhibited maximal macrophage uptake via phagocytosis and
attachment. However, the rate of internalizations is independent of by particle
size. The particle size dependence of phagocytosis is governed primarily from
the attachment of particles to the surface of macrophage. Furthermore, the
macrophage membrane ruffles is hypothesized to be the reason of

maximal
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attachment of 2–3 μm microspheres, the elimination of which through osmotic
swelling nearly diminished the peculiar size-dependence of phagocytosis. In
particular, particles of size around ~2 µm are phagocytosed more rapidly than
smaller or larger particles. Alternately, particles with hydrophobic surface are
uptake more rapidly via phagocytosis than particles with hydrophilic surfaces.
Consequentially, particle surface are modified by neutral hydrophilic polymers
such as polyethylene glycol (PEG) to modulate the phagocytosis. Nanoparticle
synthesis methods and process should be choose and modulate based upon the
targeted

size.

The

aspects

like

drug/polymer

ratio,

polymer/surfactant

concentration, solvent type and stirring/homogenization rate are some of few
important considerations [47, 55, 56].
The impact of particles shape on phagocytosis is recently beginning to be
investigated. Champion and Mitragotri [56] recently revealed from their finding
that the shape of particles has crucial impact on phagocytosis by macrophages;
the oblate ellipsoid particles are more rapidly phagocytosed than particles with
spheres or prolate ellipsoid shapes. The shape of particles triggered
phagocytosis via cell attachment and internalization. The shape-dependency of
phagocytosis is potentially linked to the actin remodeling by the macrophage
cytoskeleton, since phagocytosis is an actin–linked process. Since actin
remodeling is energy deriving process, in theory, the shape that require more
energy for actin remodeling, should be internalized slower. Therefore, the fact
that oblate ellipsoids are phagocytosed more rapidly and efficiently than prolate
ellipsoids is due to their lower aspect ratio and actin remodeling which require
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less energy for internalization. Furthermore, it has been reported that cylindrical
rods shape particles are advantageous in terms of macrophages uptake. The
mechanism reflects the preference of macrophages for engulfment of most
bacteria that have a rod shaped geometry in nature.
Surface charge of the nanoparticles has exhibited to be a major
determinant of cellular uptake, which highly depends upon cell types. For
macrophage uptake, the positively charged particles are more prone to
sequestration by macrophages in the spleen, lungs and liver. In contrast, neutral
and slightly negatively charged nanoparticles are of least preference for
macrophage uptake [45].
1.7.2 Drug Loading and Encapsulation Efficiency
Drug loading or encapsulation efficiency of a formulation is a measure of
intensity by which drug retain within polymeric matrix. In general a high drug
loading or encapsulation is required that negate the need of higher dose of
nanoparticles which otherwise administered a large volume of excipient/s. Drug
loading measures the mass of the drug entrapped within a polymeric matrix
during nanoparticle preparation compared to the mass of excipients. It is
calculated from the following equation;
Drug loading (%) = (mass of drug in nanoformulation)/ (total mass of
nanoformulation) X 100
Whereas, encapsulation efficiency of a formulation measure the ratio of
drug encapsulated in nanoformulations verses total drug added. It is important to
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purify the nanoparticles to get rid of unencapsulated drug and surface adsorbed
drug before calculating the drug encapsulation and loading parameters. Drug
loading is dependent on the process of formulation, nature of excipients, and
type of nanoparticle itself (polymeric nanoparticles, solid lipid nanoparticles,
dendrimers, etc.). For drug loading analysis, freeze dried powder of formulation is
disrupted in a solvent to release the encapsulated drug, whereas encapsulation
efficiency is measure by analyzing remaining drug in purified supernatant. A
higher drug loading indicates lesser amount of non-active excipients and small
volume of injections needed to achieve a bioequivalent drug dose [57].
1.7.3 Drug Release
The rate and extent of drug release from polymeric matrix is very crucial to
determine therapeutic efficacy of formulation. Drug release can be coined as the
opposite of drug loading. In particular, drug release is a mass transfer process
from the polymeric matrix to the surrounding release media. The release of
encased drug in a media is governed by many factors including interaction of
drug with excipients, chemical characteristics of drug and polymer and nature of
release media itself.
The rate of drug release from a matrix can be calculated using Fick’s law of
diffusion. In facts, Ficks’s law of diffusion is a mathematical simplification of a
complex process driven by
the drug release[58].

complex physicochemical parameters influencing
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1.8 ANIMAL MODELS OF HIV
Since HIV only infects human, it is a major hurdle in choosing a relevant
animal model.

HIV is specific to human immune cells, which are bound to

specific genetic factors critical for their life cycle. These include binding of HIV to
immune cells via CD4 receptor, and co-receptors CCR5 and CXCR4. Attempts
were made to fabricate those receptors over murine cell, but yet not succeed,
which in part, is due to absence of many human specific factors. Furthermore,
attempts were made to generate a chimeric strain of HIV by modifying HIV itself;
SHIV reported to replicate in monkey. Although, chimeric strain facilitates to
immune responses to vaccine construct, but differ in response that was produced
with HIV infection.

Limited successes were seen with some other notable

approach such as HIV encoded gene expression[59]. Therefore, to this end,
there is a prime need to generate relevant animal model to study HIV-1 infection.
Humanized mouse model, in this context studies as reasonable alternative.
Chronic humanized mouse model is accomplished by expression of
human transgene or transplanting human tissue into immune deficient mice.
Since these mice are immune deficient [severe combined immunodeficiency
(SCID)] that involve mutation in prkdc gene that spontaneously deplete B and T
cells population, the host-rejection of graft is lacking.
1.8.1 Human Peripheral Blood Lymphocytes (Hu-PBL) Reconstituted Mice
Humanized mouse model created by knock down of Prkdc gene
successfully exhibited immunodeficiency but with leaky production of T and B
cell, and high level of natural killer (NK) cells. Additionally, the mutation in IL-2
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(gamma chain receptor) renders the lack of IL-2 signaling in B and T cells that
leads to more efficient xenograft. Furthermore, the knock down of recombinase
activating genes 1 or 2 (Rag1/Rag2) produce xenografts with no leaky B and T
cells. Furthermore, the mutation of non-obese diabetic (NOD) gene leads to drop
down of NK cells production. Therefore, combining all mutation produce a much
stable engraftment generally referred to as NOD/scidIL- 2Rgc null (NSG)
mice[60].
The Hu-PBL reconstituted mouse is prepared by injecting human PBL
intraperitoneally into NSG mice that render them susceptible to HIV infection.
The Hu-PBL reconstituted mouse showed upregulation of Human leukocyte
antigen- DR (HLA-DR) and CCR5 that leads to production of xeno-reactive T
cells. However, due to the graft-versus-host reactions, these mice are
susceptible to die. Moreover, the mouse model is restricted by lack of
hematopoiesis and graft-versus-host response, which limit their usefulness for
chronic infection. However, the ease of preparation and availability make them
alluring for acute infection studies [61].
1.9. SIGNIFICANCE OF THE PROJECT
ABC is an antiretroviral drug used for preventing and treating HIV/AIDS. It
is a nucleoside analog acting as a chain terminator for the reverse transcriptase
inhibitor and called a NRTI as a consequence.

It is under the trade name

Ziagen. Importantly viral strains that are resistance of zidovudine or lamivudine
(3TC) can be sensitive to ABC. It has a variety of secondary toxicities that
include nausea, headache, fatigue, vomiting, hypersensitivity reaction, diarrhea,
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fever/chills,

depression,

rash,

anxiety,

URI,

ALT,

AST

elevated,

hypertriglyceridemia, and lipodystrophy. An important hypersensitivity syndrome
is associated with its use. This reaction is strongly associated with a specific
allele at the human leukocyte antigen B locus namely HLA-B*57:01.
Nonetheless, it possesses the unique property of strong penetrance of the bloodbrain barrier (BBB) and as such would be of significant use to restrict viral
infection within the brain and spinal cord and used concurrently with agents
designed to eradicate viral infection[62]. Thus, it is of significant interest to our
group of investigators.
The study will be conducted in four phases. The first will explore the
manufacturing capabilities of the novel nanoformulation. NMR tests will confirm
the formation of the pro-drug. The second phase will be in preparing the prodrug for polymer encasement with appropriate decoration with a targeting ligand
or ligands. In the second phase size, charge, morphology and polydispersity will
be measured. In the third stage, stability will be tested by taking the formulation
from storage at 4 °C and 25 °C every 10 days for 60 days and measuring the
same parameters developed in stage two.

The fourth stage will test its

antiretroviral responses by allowing monocyte derived macrophages to be
infected following 1, 5, 10 and 15 day initial exposure to the variant
nanoformulation manufactured at a spectrum of drug concentration. Toxicity
measures for the monocyte-macrophages will be performed through viability and
functional tests.
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The studies will be focused on developing folic acid (FA) targeted, longacting parenteral nanoformulations of Abacavir prodrugs. The overarching goals
would be to extend the pharmacokinetic (PK) and pharmacodynamics (PD)
profile of native hydrophilic counterpart i.e. ABC, specifically targeting them to
macrophage receptors using folic acid ligand coating.
Long-acting parenteral nanoformulations circumvents several pitfalls of
conventional oral drug delivery like treatment off-target toxicity, poor PK and
biodistribution, drug-drug interactions and limited therapeutic end point. The longacting nanoformulations results in targeted drug delivery to viral reservoir sites
with uniformity in PK parameters. Several potent antiretroviral agents were
discontinued

due

to

their

poor

PK

and

undesirable

physicochemical

characteristics such as poor dissolution, instability in GIT fluids etc. Formulating
such drugs as long-acting nanoformulation can circumvent such issues and
probability of getting these drugs back to market is high. Because in
nanoformulation encased drug is protected within polymeric matrix and inside
stable intracellular compartments, the probability of drug-drug interaction with
other drug and adverse effects will be considerably reduced[63].
The other important implication of long-acting nanoformulations is by
reducing the dosing frequency and overall dose that lead to improved patient
compliance by decreasing treatment associated anxiety in patients. Furthermore,
long-action nanoformulations can ameliorate viral resistance and patient
adherence against ART[64]. Specially, this will be very beneficial to the patients
with concomitant substance abuse, which are usually non-adherent to treatment
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regimens. Therefore, such patient’s population is usually not treated with ART
because of higher risk of transmission of resistant species of HIV-1 to uninfected
individuals.
In future, with long-acting nanoformulations platforms using robust
manufacturing procedures, once six months or even less frequent dosing
regimen can be achieved. Such dosing regimen holds promising in HIV
eradication as of their ability to reach deep penetrating in to HIV reservoir, which
otherwise formidable to conventional dosing regimen. Even though complete
eradication is not possible, the diminished of viral rebound can be feasible with
such dosing regimen.

Additionally, it is possible to administered long-action

nanoformulations in to individual living in high-risk population as pre-exposure
prophylaxis, or PrEP.
Long-acting nanoformulations by constructing macrophage-mediated
delivery system even with frequent dosing could drastically improve the
therapeutic outcome by penetrating deeper into anatomical HIV-1 reservoir. The
ability of long-acting NanoART to penetrate deeper into these HIV reservoir
tissue would considerably suppress viral production manes it provide a mean for
immune system to better handle co-morbid conditions.

This would turn very

beneficial for patient with co-morbid conditions living in resources limited setting.
Furthermore, the ability of long-acting NanoART to circumvent drug resistance
and decrease drug associated toxicities present a means to reduce the cost
associated with HIV management, especially in resource-limited settings[64].
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Figure 1.1. Life cycle of HIV Virus [2]
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Figure 1.2. Time course of HIV Disease progression without Therapy [15]
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Figure 1.3. Development of ART targeting different stages of HIV life cycle
[5]
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Figure1.4. HIV reservoirs in HIV patients receiving cART [34]
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Figure 1.5. Macrophage particle uptake in different organs including the
lungs, liver, spleen and kidneys are dictated by size, shape and surface
charge of nanoparticles [45]
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CHAPTER 2
HYPOTHESIS AND SPECIFICS AIMS
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2.1. HYPOTHESES
We proposed that macrophage-targeted nanoformulations of Abacavir prodrugs
will facilitates uptake, retention and antiretroviral efficacy in cultured monocytederived macrophages (MDM), and will improve pharmacokinetics, biodistribution,
and pharmacodynamics efficacy in murine models of HIV-1.
Our lab has pioneered in developing long-acting NanoART that may
facilitate patient compliance by permitting once weekly or bi-weekly dosing
regimen. It has been reported that macrophage are the first cells pools that
encounter HIV first, and play a critical role through the HIV prognosis. Also, the
natural ability of macrophage to reside at the site of virus hideout i.e. lymphnodes, spleen, liver etc. further aid the beneficial of homing the drug depot at the
site of action. Thus we posit that macrophage-targeted drug delivery can improve
the PK profile and render the biodistribution at right place, thus improve
therapeutic efficacy while reducing off-target toxicity of drug. We tested this
hypothesis in following two parts of the projects;
Project 1: A phosphoramidate prodrug of abacavir (P-ABC), was synthesized to
improve the biological activities of the parent nucleoside. The idea is to increase
intracellular nucleoside 5’-O-triphosphate levels by bypassing rate-limiting
monophosphorylation. This would lead to decreased activity of the virus encoded
reverse transcriptase. A prodrug could readily incorporate into poly(lactic-coglycolic acid) (PLGA) nanoparticles and as a consequence affect the efficacy of
long-acting P-ABC nanoformulations as measured by pharmacokinetics and
pharmacodynamics (PK and PD) tests
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Project 2: A myristic acid derived hydrophobic prodrug of ABC (M-ABC) was
synthesized. M-ABC would then be loaded at high concentrations into a
decorated

polymer

coating

with

targeting

ligands

aimed

to

improve

biodistribution, drug half-life and antiretroviral efficacy in viral target CD4+ T cells
and monocyte-macrophages. To this end we incorporated M-ABC into poloxamer
(P407) then decorated the particle with folic acid. These modifications positively
affect macrophage uptake and antiretroviral efficacy
For both projects, hypothesis will be tested under following specifics aims;
Specific Aim 1: Synthesis, Characterization and Nanoformulation of
Abacavir Prodrugs
The objective was to synthesize phosphoramidate prodrug (PABC)
(project 1), and myristoylated prodrugs (MABC) (project 2) of Abacavir. The
prodrugs were characterized using 1H-NMR, FTIR and mass spectroscopy.
Antiretroviral activity as measured by the EC50 was compared amongst the
PABC, M-ABC and frees ABC in MDM. The prodrugs were nanoformulated using
PLGA (project 1) and poloxamers (P407) or folate conjugate poloxamers (FAP407) (project 2) as excipients. Nanoformulated prodrugs were characterized for
physicochemical parameters such as; size, size distribution (PDI), surface
charge, drug loading and stability.
These parameters are of key importance in determining their cell
cytotoxicity and cell interactions. The folate coating integrity determines the
macrophage target ability, and thus antiretroviral efficacy and in vivo PK/PD fate
of nanoformulated prodrugs.
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Specific Aim 2: In Vitro Characterization of Nanoformulated Prodrugs in
MDM
The objectives of this aim were to (a) determine the uptake, retention and
antiretroviral efficacy of nanoformulated prodrugs in MDM; (b) study the
intercellular trafficking of nanoformulated prodrugs in MDM; and (c) to assess the
cytotoxicity of nanoformulated prodrugs in MDM. The overarching goal of this aim
was to develop superior nanoformulation for animal testing that can be
extrapolated for human testing in near future.
Specific aim 3: PK and PD Characterization of Nanoformulated ABC
Prodrugs in Wild Type Mice and in Murine Models of HIV-1.
Optimized nanoformulations for both prodrugs from aims 1 and 2 were
evaluated in murine models of HIV/AIDS. With optimized formulations (a) the PK
testing in Balb/cJ mice were assessed to determine drug levels in plasma and
tissue, and (b) correlated to antiretroviral efficacy in HIV infected NOD/scid-gcnull
(hu-PBL-NSG) mice. The formulations were administered parenterally to Balb/cJ
and hu-PBL-NSG mice. The drug bioavailability and therapeutic end pints were
determined.
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CHAPTER 3
CREATION OF AN ABACAVIR
NANOFORMULATED PHOSPHORAMIDATE PRODRUG
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3.1. INTRODUCTION
Abacavir (ABC) is a nucleoside reverse transcriptase inhibitor (NRTI) that
is used in combination with non-nucleoside reverse transcriptase inhibitors
(NNRTIs), protease inhibitors (PIs) and integrase strand transfer inhibitors
(InSTIs), as components of a first line treatment regimen for human
immunodeficiency

virus

(HIV)

infection

by

the

National

AIDS

Control

Organization [1, 2]. Notably, the viral strains that are resistant to zidovudine or
lamivudine are sensitive to ABC [3]. However, ABC is associated with a dose
dependent hypersensitivity response linked to the HLA-B*5701 allele that can be
fatal if therapy is not discontinued [4]. Inefficient phosphorylation of ABC into its
active metabolite carbovir-5’-triphosphate (CBV-TP) compromises the overall
efficacy resulting in required high therapeutic doses of ABC [5]. Metabolic studies
of ABC revealed that adenosine phosphotransferase predominantly metabolizes
ABC to ABC-monophosphate (ABC-MP), which is subsequently converted to
carbovir-5-monophosphate (CBV-MP) by cytosolic deaminase. CBV-MP is then
anabolized to CBV-TP by cellular kinases. CBV-TP is the biologically active
metabolite that terminates DNA synthesis by inhibiting the virus-encoded reverse
transcriptase (RT) [5]. However, ABC has been shown to be a poor substrate for
adenosine phosphotransferase, resulting in inefficient conversion to the
monophosphate derivative (ABC-MP) [6]. Monophosphorylation is, thus, the ratelimiting step in determining the efficacy of ABC. In fact, the efficacy of the
majority of nucleoside analogs, not only ABC, is compromised by the inefficient
first-step monophosphorylation. Stavudine (d4T), zalcitabine, didanosine and
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gemcitabine are examples where relatively poor monophosphorylation severely
compromises the efficacy of the drug [7-9].
To overcome such challenges, several attempts have been made to
deliver phosphorylated nucleoside analogs directly into the infected target cells
[10]. ProTide technology that generates phosphorylated nucleoside analogs
(pronucleotides) is widely utilized to bypass the poor phosphorylation step of
nucleosides. Pronucleotides are phosphorylated prodrugs in which a masked
phosphate moiety is covalently linked to the hydroxyl group of the nucleosides.
Masking of the phosphate moiety through a benzyl ring at one end, and a Lalanine methyl ester at the other end improves the hydrophobic nature of these
compounds, and thus facilitate cellular entry of the phosphorylated prodrug [11].
The concept of ProTide technology was first introduced for cancer treatment in
1982 with the synthesis of the pronucleotide prodrug, cytosine arabinoside 5ʹmonophosphate [12]. The clinical efficacy of the antiviral pronucleotides of
adefovir dipivoxil and tenofovir disoproxil was confirmed and the drugs approved
by the FDA [13-15]. Several other antiviral and anticancer pronucleotide prodrugs
are under clinical development [10].

It is important to know whether a

pronucleotide prodrug of ABC can result in improvement of antiretroviral activity.
McGuigan et al. [16] reported the first application of ProTide technology to ABC
and observed that the anti-viral potency of the ABC pronucleotide was improved
significantly (70-fold) in human T4 lymphocyte CEM cells.
Lack of sustained and effective viral suppression rests in the inability of
drugs to specifically target HIV viral reservoirs [17] which include lymph nodes,
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gut-associated lymphoid tissue (GALT), spleen, central nervous system (CNS)
and central memory lymphocytes and myeloid cells contained within the
lymphoreticular tissues [18-20]. Lack of achievement of optimal drug levels in
these reservoir sites can lead to the establishment and perpetuation of viral
sanctuaries, and thus treatment failure [21, 22]. We posit that development of an
effective delivery scheme for nucleoside prodrugs to extend plasma drug half-life
and facilitate drug delivery into HIV anatomical reservoirs would increase their
therapeutic utility.
In this study, a pronucleotide prodrug of ABC (PABC) was synthesized and
encapsulated into a lipid-PLGA based nanocarrier. The mixed lipid outer covering
of the PLGA core enabled the sustained release of drug cargo over an extended
period of time. Antiretroviral efficacy of PABC and nanoformulated PABC were
evaluated in human macrophages and a humanized mouse model of HIV
infection.
3.2. MATERIALS AND METHODS
3.2.1. Chemicals
Abacavir (ABC) sulfate, phenyl dichlorophosphate, L-alanine methyl ester
hydrochloride salt and poly (D, L-lactide-co-glycolide; lactide:glycolide (75:25),
mol wt 66,000-107,000) (PLGA) were purchased from Sigma-Aldrich (St. Louis,
MO). ABC sulfate was titrated with sodium bicarbonate to convert it into freebase. DSPE-mPEG2k (distearoyl-phosphatidylethanolamine-methyl-polyethylene
glycol conjugate-2000), DSPC (1, 2-distearoyl-sn-glycero-3-phosphocholine) and
DSPG (1, 2-distearoyl-sn-glycero-3-phosphoglycerol) were purchased from
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CordenPharama (Cambridge, MA). Phosphate-buffered saline (PBS), Optima
grade water and high performance liquid chromatography (HPLC) grade
acetonitrile, methanol, dichloromethane (DCM) and tetrahydrofuran (THF) were
purchased from Fisher Scientific (Fair Lawn, NJ). Rabbit anti-human antibodies
to Rab5, Rab7, Rab11, and Rab14, and AlexaFluor 488 conjugated goat antirabbit IgG were purchased from Santa Cruz Biotechnology (Dallas, TX). A dry
argon atmosphere was practiced to perform the chemical reactions. Flash silica
gels (32-63 μm) from Dynamic Adsorbents Inc. (Norcross, GA) were used to
perform flash chromatography. Reactions were monitored by thin-layer
chromatography using precoated silica plates (F-254 (250 μm) from SiliCycle Inc;
Quebec City, Quebec, Canada) and visualized using ninhydrin or KMnO 4 staining
or UV fluorescence. Fluorescein-modified PLGA was synthesized as described
[23]
3.2.2. Synthesis of PABC
Step 1. Synthesis of phenyl (methoxy-L-alaninyl) phosphorochloridate:
Phenyl (methoxy-L-alaninyl) phosphorochloridate was synthesized as previously
described [16]. Briefly, phenyl dichlorophosphate (1 mol, 3.02 g) and L-alanine
methyl ester hydrochloride salt (1 mol, 2.00 g) was suspended in anhydrous
DCM, and cooled to -80 °C. To this mixture, a pre-cooled (-80 °C) solution of
anhydrous trimethylamine (2 mol, 2.90 g) in DCM was added drop-wise, and the
reaction was stirred and gradually warm to room temperature over 16 h under an
inert argon atmosphere. The solvent was removed using a rotavap to yield a
white solid that was resuspended into diethyl ether and filtered. The filtrate was
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concentrated by rotavap to give colorless oil that was resuspended in anhydrous
THF, and used without further purification for the subsequent coupling step.
Step 2. Coupling of phenyl (methoxy-L-alaninyl) phosphorochloridate with
ABC.

ABC (1 mol) was dried by azeotroping from anhydrous pyridine, then

suspended in anhydrous THF and cooled to 0°C under argon. Tertbutylmagnesium chloride (2 mol, 1.0 M solution in THF) was added to the mixture
and stirring was continued for 10 min. Phosphorochloridate (3 mol, solution in
THF) was added drop-wise to the deprotonated ABC and the reaction was stirred
for 90 h at room temperature. The reaction was then cooled to 0°C and
quenched with aqueous saturated ammonium chloride solution. The solvent was
removed under vacuum, and the pure prodrug was isolated and purified using
silica column chromatography. PABC was characterized using FTIR and 1H-NMR
spectroscopy. FTIR spectra of PABC was recorded and compared with that of
ABC using a UATR-2 FTIR spectrometer (PerkinElmer Inc. Waltham, MA). 1HNMR spectra were recorded on a Varian INOVA 500 spectrometer. 1H-NMR data
was recorded in ppm downfield using trimethylsilyl as an internal reference
standard.
3.2.3. Human Peripheral Blood Cell Isolation and Culture
Human peripheral blood lymphocytes (hu-PBL) and monocytes were
isolated by leukapheresis from HIV-1 and -2 and hepatitis seronegative donors,
and purified by countercurrent as described previously [24]. For cellular uptake
and antiretroviral efficacy studies monocytes were plated in 12-well culture plates
at 1.5 X 106 cells / well and differentiated into macrophages (MDM) [25] by
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culturing in DMEM with 1% glutamine, 10% heat-inactivated pooled human
serum, 1000 U/ml MCSF, 10 μg/ml ciprofloxacin and 50 μg/ml gentamicin for 710 days. Human peripheral blood lymphocytes were used for animal
reconstitution as described below.
3.2.4. Antiretroviral Activity of PABC
The antiviral activity of PABC and native ABC against HIV-1 were
determined in MDM [5]. MDM were incubated with various concentrations of ABC
or PABC for 60 min followed by infection with HIV-1ADA at a multiplicity of
infection (MOI) of 0.01 infectious viral particles/ cell for 4 h. The MDM were
washed extensively with PBS to remove excess virus particles. The cells were
incubated an additional 10 days in the presence of the same concentration of
drug used before infection. Cell culture medium was changed every other day
with replacement of equivalent drug containing media. At day 10 post infection,
supernatants were collected and analyzed for HIV-1 reverse transcriptase (RT)
activity [26].
3.2.5. Synthesis of Lipid-PLGA hybrid PABC Nanoparticles
PBAC-loaded nanoparticles (NPs) of a mixed lipid outer shell and
biodegradable PLGA inner core were prepared using the single - emulsion
solvent evaporation method [27] and designated as lipid-nanoPABC (L-NPABC).
PLGA and PABC (weight ratio 4:1) were dissolved in 2 ml of DCM to constitute
the oil phase of the single emulsion. For the aqueous phase DSPG, DSPEmPEG2k, and DSPC (weight ratio of 1:5:10) were dissolved in chloroform,
followed by slow solvent evaporation and overnight drying in a vacuum
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desiccator. The formed lipid film was hydrated with 8 ml phosphate buffer (10
mM; pH 7.4) followed by vigorous mixing with vortex. The oil phase was then
added dropwise to the aqueous phase with stirring. The mixture was then cooled
on an ice bath and sonicated using a probe sonicator (Cole Parmer, Vernon Hills,
IL, USA) at 20% amplitude until the desired particle size of ~250 nm was
achieved. The DCM from the emulsion droplets was evaporated using a Buchi
Rotavapor (New Castle, DE). Unencapsulated drug and polymers were removed
by centrifugation at 20,000 × g for 20 min. After washing three times, purified NP
pellets were resuspended in 10 mM phosphate buffer (pH 7.4) with 0.2% w/v
P407 poloxamer as cryoprotectant, followed by freeze-drying to obtain a fine
powder. The control formulation without lipid outer covering was fabricated using
5% polyvinyl alcohol (PVA) (w/v) as an emulsifier, and designated as NPABC.
Fluorescently labeled L-NPABC were fabricated in the same manner using a
mixture of fluorescein-labeled PLGA and unlabeled PLGA at a weight ratio of 3:1.
The dye-labeled PLGA was synthesized as reported [23].
3.2.6. Physicochemical Characterization of PABC Nanoparticles
3.2.6.1. Nanoparticle size and charge
Size, size distribution (PDI) and surface charge of drug loaded NPs were
measured by dynamic light scattering (DLS) using a Malvern Zetasizer, Nano
Series Nano-ZS (Malvern Instruments Inc, Westborough, MA). Nanoparticle
suspensions were diluted with water to optimize mass intensity then vortexed.
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3.2.6.2. Nanoparticle morphology
The morphology of drug loaded NPs was determined by scanning electron
microscopy (SEM) on a Hitachi S4700 field-emission scanning electron
microscope (Hitachi High Technologies America Inc, Schaumburg, IL, USA).
Particle surface morphology and the outer shell lipid coating over the PLGA inner
core were characterized by transmission electron microscopy (TEM) using a
Hitachi H7500 Transmission Electron Microscope (Hitachi High Technologies
America Inc, Schaumburg, IL, USA). For TEM analysis, the NP suspensions
were diluted in Milli-Q water and placed onto a copper grid, and air-dried at room
temperature. For contrast enhancement, one drop of a 2% aqueous solution of
sodium phosphotungstate was used as a negative stain. The images were
recorded under bright-field conditions with exposure times of 2 s, and an
accelerating voltage of 200 kV.
3.2.6.3. Drug loading and encapsulation efficiency (EE)
The amount of drug encapsulated in the polymeric matrix was determined
by high performance liquid chromatography (Waters Breeze HPLC system,
Waters Inc., Milford, MA, USA). Freeze-dried NPs (1 mg) were sonicated in 50 µl
THF, diluted with 1 ml methanol, vortexed for 10 s, then centrifuged at 10,000 × g
for 20 min. The supernatant was further diluted in mobile phase (35:65 v/v;
acetonitrile/ 10 mM KH2PO4, followed by filtration using a 0.2 mm PVDF syringe
filter. The sample components were separated on a Kinetex reversed phase C18 column ((5 µm, 150 × 4.6 mm), Phenomenex, Torrance, CA) using a flow rate
of 1.0 ml/min. The column effluent was monitored at 220 nm. The percentage
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drug loading was calculated as the weight percentage of PABC encapsulated in
a given mass of lyophilized NPs. The EE was calculated as (actual amount of
drug encased in NPs) / (initial amount of drug used in NPs preparation) × 100%.
3.2.6.4. In vitro nanoparticle drug release
The in vitro release profile of PABC from L-NPABC or NPABC was
determined using dialysis [28].

Specifically, in triplicate the drug-loaded NPs

were dispersed in 1 ml PBS (0.1 M, pH 7.4) and placed in a dialysis pouch
(cellulose membrane, mw cut-off 10kDa) in 30 ml of PBS with stirring at 37 °C. At
0.5, 1, 2, 4, 8, 12 and 48 h, 100 µl of the PBS was collected with replacement of
an equal amount of fresh PBS. PABC in the aliquot was quantified by HPLC as
described above.
3.2.7. MDM Uptake of PABC Nanoformulations
Uptake of PABC nanoformulations and free PABC were determined in
human MDM [29, 30]. MDM were incubated with 100 µM free PABC or L-NPABC
for various times from over 24 h. At each time point, MDM were washed 3 times
with PBS to remove excess NPs or free drug. MDM were scraped into 1 ml of
fresh PBS then pelleted by centrifugation at 950 x g for 8 min. The cell pellet was
reconstituted in 200 µl of methanol, probe sonicated for 10 sec followed by
centrifugation at 20,000 χ g for 10 min. The supernatant was analyzed for drug
content using HPLC. Cytotoxicity of PABC or nanoformulated PABC was
determined using MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide) [30]. Briefly, MDM were treated with 50, 100 and 200 µM free PABC or
nanoformulated PABC for 24 h. Following washing with PBS, the MDM were
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incubated with 200 µl of MTT working solution (0.5 mg/ml diluted in MCSF free
media) for 30 min at 37°C. Dimethyl sulfoxide (DMSO; 200 µl/well) was added to
the cells and incubated for 5 min at 25˚C. The absorbance at 490 nm was
measured using a SpectraMax M3 Microplate reader (Molecular Devices,
Sunnyvale, CA, USA).
3.2.8. Antiretroviral Activity of Nanoformulated PABC
To determine antiretroviral activity of nanoformulated PABC, MDM were
treated with 100 µM native ABC, free PABC or L-NPABC for 8 h. MDM were then
washed 3 times with PBS to remove excess drug or NPs. On day 1, 5, 10 or 15
following treatment, MDM were infected with HIV-1ADA at a MOI of 0.01 infectious
viral particles /cell for 18 h. HIV-1 RT activity was measured in culture medium on
day 10 post infection to determine viral replication [26]. As a secondary
determinant of viral infection HIV-1 p24 protein expression in the MDM was
determined by immunostaining [31].
3.2.9. PABC Nanoparticle Subcellular Co-localization
To evaluate the subcellular trafficking of nanoformulated PABC, human
monocytes

(5 X 105 cells/ well) were cultured in an 8 well Lab-Tek II CC2

chamber slide and differentiated into macrophages as described previously [31,
32]. MDM were treated with 100 µM CF633-labeled L-NPABC for 8 h. The cells
were washed 3 times with PBS to remove excess NPs. The cells were fixed with
4% PFA for 30 min, permeabilized with 5% Triton-X in PBS for 15 min, and
blocked with 5% BSA and 0.1% Triton-X in PBS for 15 min. The cells were
washed with 0.1% Triton and incubated overnight at 4˚C followed by 1 h at room
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temperature

with

primary

antibody

(1:50

dilution)

against

endocytic

compartments; early endosomes (Rab5; sc-28570), late endosomes (Rab7; sc10767) and recycling endosomes (RAB11 and Rab14; sc-9020 and sc98610).
The cells were washed with 0.1% Triton-X in PBS and incubated with
corresponding AlexaFluor 488-conjugated secondary antibody for 90 min at room
temperature. ProLong Gold anti-fade reagent with DAPI (4, 6-diamidino-2phenylindole) was added and the slide cover slipped. Cells were imaged with an
LSM 510 microscope using a 63X oil lens (Carl Zeiss Microimaging, Inc., Dublin,
CA, USA).
3.2.10. Pharmacodynamics
For pharmacodynamics studies, 8-10 week old NOD/SCID/IL2Rγc −/−
(NSG) mice were mice were obtained from a University of Nebraska Medical
Center (UNMC) breeding colony. Breeding colony maintenance and animal
pharmacodynamics studies were conducted according to protocols approved by
the University of Nebraska Medical Center Institutional Animal Care and Use
Committee. For pharmacodynamics studies, the mice were reconstituted with
25×106 hu-PBL per mouse by intraperitoneal injection one week prior to
treatment [33]. Following hu-PBL reconstitution, mice were treated with 100
mg/kg of native ABC or an equivalent ABC dose of L-NPABC. Twenty-four hours
after drug treatment, mice were injected intraperitoneally with HIV-1ADA using a
104 tissue culture infectious dose 50(TCID50)/mouse. Mice were sacrificed on
day 10 post-infection, and blood and tissues were collected for fluorescenceactivated cell sorting (FACS), HIV-1p24 staining and viral load analysis. Blood
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samples were collected into Ca2+-EDTA-coated tubes. The spleen cells were
isolated at the time of sacrifice and suspended in PBS. The expression of human
CD45, CD3, CD4 and CD8 immune markers was determined in blood and spleen
cells using flow cytometry as previously described[34]. Splenic RNA was
extracted using TRIzol (Invitrogen). Quantitative RT-PCR was conducted to
determine the human CD45, mouse GAPDH RNA and HIV-1gag RNA levels.
For HIV-p24 antigen staining, spleens were fixed in 10% neutral buffered
formalin and paraffin embedded. Serial 5 µm thick sections were cut, mounted
on glass slides, and stained with human leukocyte antigen HLA-DR (dilution
1:100) and mouse monoclonal antibodies for HIV-1p24 (1:10 dilution),
respectively. The antimouse, polymer based horseradish peroxidase-conjugated
DAKO envision system was used as a secondary antibody for detection of HLADR and HIV-1 p24 using 3, 3-diaminobenzidine (DAB). Mayer’s hematoxylin stain
was used as a nuclear counterstain. The images were visualized with a Nikon
Eclipse E800 microscope using NIS-Elements and a 40X objective. The number
of HLA-DR + and HIV-1p24+ cells per section were counted and expressed as
the percentage of HIV-1p24+ cells per HLA-DR+ cells in a section.
3.3. RESULTS
3.3.1. PABC Synthesis and Characterization
A phosphoramidate prodrug of abacavir (PABC) was synthesized to
improve the biological activity of the parent nucleoside. The goal was to increase
intracellular nucleoside 5’-O-triphosphate levels by circumventing the rate-limiting
monophosphorylation of ABC by phosphotransferase as previously reported [5].
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This would lead to decreased activity of the virus encoded RT [16]. PABC was
synthesized by derivatization of the native compound with an enzyme cleavable
phosphorochloridate moiety (figure 3) following a previously reported method,
[16]. The covalent linkage of phosphorochloridate to the 5’-O-hydroxyl group of
ABC was confirmed by nuclear magnetic resonance, Fourier transform infrared
spectroscopy and tandem mass spectrometry ( 1H-NMR, FTIR and MS/MS). As
shown in Figure 3.2 A, the multiplet at 7.1-7.4 ppm in the 1H-NMR spectrum
corresponds to five protons from the benzene ring of the derivatizing phosphate
moiety. The singlet at 3.70 ppm and the two doublets at 1.38 ppm represent the
three methyl ester protons and gamma protons from alanine on the phosphate
group. Successful synthesis was validated by comparison of the FTIR spectra of
PABC to that of native ABC (Figure 3.2 B). Peaks at 1739 cm-1 and 1208 cm-1 in
PABC FTIR spectrum, corresponding to carbonyl (C=O) and phosphate group
(P=O) stretching of the phosphochloridate moiety, confirmed the conjugation of
phosphochloridate with the ABC molecule. The peaks at 1588 cm-1 in the PABC
and ABC FTIR spectra corresponded to CH2 stretching of the native aromatic
ring. Additionally, the peaks at 1035 cm-1 and 1021 cm-1 in the ABC and PABC
spectra correspond to NH2 broadening of the parent compound. Infusion into a
Waters Xevo TQS micro triple quadrupole tandem mass spectrometer confirmed
a molecular mass ion of 528.2, which corresponds to ABC with one
phosphochloridate modification (data not shown). The details for the 1H-NMR
spectrum are; (CDCl3): 7.49 (2s, 1H), 7.1-7.4 (m, 5H), 6.05-6.15 (m, 1H), 5.875.93 (m, 2H), 5.82 (br, 1H), 5.49-5.55 (m, 1H), 4.88 (br, 2H), 4.13-4.29 (m, 2H),
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4.0-4.1 (m, 1H), 3.70 (s, 3H), 3.10-3.22(m, 1H), 3.01 (br, 1H), 2.73-2.85 (m, 1H),
2.06 (br, 2H), 1.60-1.80 (m, 1H), 1.38 (2d, 3H), 0.80-0.90 (m, 2H), 0.63 (app s,
2H).
3.3.2. Antiretroviral Activity of PABC
The antiretroviral activity of PABC compared to native ABC was
determined in human MDM. MDM were treated with various concentrations of
PABC or ABC bracketing EC50 for ABC (100 nM) prior to and continuous with
HIV-1ADA infection [5]. The HIV RT activity was assessed in infectious culture
medium collected on day 10 day post-infection [26]. As shown in Figure 3.3 the
EC50 for antiviral activity of PABC was improved 10-fold compared to native ABC.
The EC50 for the PABC was ~15 nM compared to 150 nM for the native ABC.
3.3.3. Preparation and Characterization of lipid-PLGA hybrid NPs
Lipid-PLGA hybrid NPs loaded with PABC (L-NPABC) were synthesized
using a modified single emulsion solvent evaporation technique as described
previously [35]. A mixed lipid outer shell consisting of a 10:5:1 weight ratio of
DSPC: DSPE-PEG2k: DSPG was incorporated over the drug loaded PLGA inner
core to sustain the release of loaded cargo (Figure 3.5). A 2:1 weight ratio of
PLGA core to lipid shell was used. In contrast to its hydrophilic native counterpart
(ABC), PABC was readily incorporated into PLGA NPs. The percentage drug
loading using hydrophilic native ABC was less than 1% (data not shown). A
control formulation, without the outer lipid layer, was synthesized using 5% PVA
(w/v) as the emulsifier in the same manner as L-NPABC and designated as
NPABC. NP size, charge and surface morphology were characterized by DLS,
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SEM and TEM. Table 1 summarizes the characteristics of NPABC and LNPABC. The narrow PDI displayed by the nanoformulations indicates a relatively
homogenous particle distribution. Furthermore, the morphology of L-NPABC, as
determined by SEM and TEM, was observed to be spherical and around 200 nm
in size, correlating with the size measured by DLS (Figure 3.4A, 3.4B).
Examination of surface morphology by TEM confirmed an outer lipid covering
over a PLGA core, potentially contributing to the sustained release of encased
cargo [36] (Figure 3.5). As shown in Figure 3.5, in contrast to NPABC, the lipid
layer of L-NPABC enabled sustained release of PABC from the PLGA matrix. A
burst release was observed during the first 1 h for NPABC with more than 50% of
drug released, and more than 95% of PABC released in the first 8 h. In contrast
only 20% of PABC was released in the first 1 h for L-NPABC and less than 50%
of PABC was released during the first

8 h., The cumulative PABC release

reached 65% on day 1 and 73.5% on day 2 for L-NPABC compared to 95.2% on
day 1 and 99.4% on day 2 for NPABC. Based upon the sustained drug release
and improved drug encapsulation L-NPABC was selected for further in vitro and
in vivo studies.
3.3.4. Macrophage Uptake
MDM uptake of L-NPABC and free PABC was determined over 24 h.
MDM were exposed to 100 μM free PABC or L-NPABC for various times and
drug uptake was quantified using HPLC. As shown in Figure 3.6A, MDM uptake
of PABC was maximum at 8 h for both free PABC and L-NPABC. At 8 h, the cell
PABC levels for L-NPABC was 7.6 ± 0.8 μg/106 cells, which was 6-fold greater
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than that for free drug (1.2 μg/106 cells). After 8 h, cell drug levels declined, and
drug levels for L-NPABC and free drug at 24 h were 2.5 ± 0.3 and 0.32 μg/10 6
cells, respectively.
3.3.5. Antiretroviral Activity of PABC Nanoformulations
To determine whether improved encapsulation and sustained release of
PABC encased into L-NPABC would translate to improved antiretroviral activity
compared to free PABC or native ABC, MDM were treated with 100 µM native
ABC, free PABC or L-NPABC for 8 h. At day 1, 5, 10 or 15 post-treatment MDM
were infected with HIV -1ADA. HIV RT activity and HIV p24 antigen expression
were assessed in infectious supernatant and adherent MDM on day 10 postinfection. Decreased RT activity in MDM treated with nanoformulated PABC
revealed that L-NPABC consistently decreased antiretroviral activity compared to
that of free ABC or PABC. The RT activity was not decreased in the supernatant
collected from MDM treated with native ABC, indicating either no uptake or rapid
clearance of the native drug. However, HIV replication in MDM was suppressed
by 95% using native ABC treated 24 h after HIV-1 exposure indicating drug
penetration into the cells (data not shown). HIV replication using free PABC was
reduced by 100% at day 1 40 ± 5.4% at day 5, and minimal to no inhibition at
days 10 and 15. In contrast L-NPABC suppressed viral replication by 100% at
days 1 and 5 and 78 ± 3.5% and 52 ± 4.5% at days 10 and 15, respectively
(Figure 3.6B). HIV p24 antigen expression in adherent MDM was assessed at 10
day post infection to cross validate the results for RT activity. P24 antigen
staining showed increased viral infection from days 1 to 15 in MDM treated with
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free ABC or PABC, whereas minimal to no p24 antigen was detected in MDM
treated with L-NPABC at all time points (Figure 3.6C ).
3.3.6. Subcellular NPs Localizations
Sub-cellular localization of fluorescein-labeled L-NPABC was determined
using confocal microscopy. The physicochemical parameters of the fluoresceinlabeled L-NPABC were similar to that of the unlabeled nanoformulations (data
not shown). MDM were treated with 100 µM fluorescein-labeled L-NPABC for
8h.

The cells were washed, fixed, and stained with Rab5, -7, -11, and -14

endolysosomal protein antibodies as described previously [31, 32]. Rab5 and
Rab7 antibodies identified the early and late endosomal compartments, whereas
Rab11 and Rab14 antibodies identified recycling endosomal compartments. As
shown in Figure 3.7A, the L-NPABC was co-localized predominantly in recycling
endosomal compartments (Rab11 and Rab14), and observed as a yellow
punctate pattern throughout the cytoplasm and perinuclear cell regions in the
merged images of green compartments and red NPs.

The percent overlap

between endosomal compartments and L-NPABC were determined using
ImageJ software and JACoP plug-in. L-NPABC showed significantly greater colocalization with recycling endosomal compartments (38 ± 2.5% and 45 ± 1.5 %;
Rab11 and Rab14) than with early and late endosomal compartments (17 ± 1.4
% and 20 ± 2.3 %; Rab5 and Rab7) (Figure 3.7B ).
3.3.7. Pharmacodynamics
Antiretroviral efficacy of L-NPABC compared to native ABC was assessed
in hu-PBL reconstituted NSG mice. Reconstituted mice were given a single
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subcutaneous injection of 50 mg/kg of native ABC or an equivalent ABC dose of
L-NPABC. Mice were infected with HIV-1ADA 24 h following treatment and viral
replication was determined at day 10 post infection (Figure 3.8A). As a measure
of HIV infection, the numbers of HIV-1 p24+ cells among HLA-DR+ cells were
evaluated in paraffin-embedded spleen sections.

As shown in Figure 3.8B,

compared to the untreated HIV infected controls, ABC treatment did not elicit
protection from viral infection. In contrast, mice treated with L-NPABC showed a
significantly lesser percentage of HIV-1p24+ cells per HLA-DR+ cells in spleen
compared to untreated mice or mice treated with native ABC (Figure 3.8C). HIV1 infection results in a gradual decline of CD4+ T cells in hu-PBL reconstituted
NSG mice [37-39]. Thus, as a measure of viral infection, the CD4+ /CD8+ T-cell
ratios were determined using FACS analysis of spleen cells and blood cells
collected at study termination. Decreased numbers of CD4+ T cells and CD4+
/CD8+ T-cell ratios were observed in spleens from mice infected with HIV-1 with
no treatment or ABC treatment. However, the CD4+ /CD8+ T-cell ratios in
spleens from mice treated with L-NPABC prior to HIV infection were not
decreased. The CD4+ /CD8+ T-cell ratios in spleen from L-NPABC treated mice
were significantly higher than in mice infected with HIV-1 with no treatment or
ABC treatment and were comparable to those from uninfected control mice
(Figure 3.8D). However, there were no significant differences in CD4+ /CD8+ Tcell ratios among treatments groups and uninfected control mice in blood (data
not shown). We also measured HIV-1gag RNA levels in spleen by reverse
transcriptase polymerase chain reaction (RT-PCR) assay. L-NPABC treatment
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suppressed HIV-1gag gene expression in spleen to 5 -folds. In contrast,
treatment with native drug did not suppress HIV-1gag expression (Figure 3.8E).
3.4. DISCUSSION
Pronucleotides of ABC have been synthesized by others and provided two
therapeutic advantages; (i) the direct administration of ABC-MP improved the
antiviral efficacy in human macrophages and T-lymphocytes by circumventing
the rate-limiting phosphorylation step and (ii) the deamination of ABC to CBV
was bypassed, eliminating the CBV-associated renal and cardiac side effects [5].
Thus, direct administration of ABC-MP not only improved antiviral efficacy, but
also improved the safety profile of ABC.

With these results in mind, we

synthesized PABC with 54% final yield and validated the synthesis using 1HNMR, FTIR and mass spectrometry. The EC50 for HIV suppression was reduced
10-fold in human MDM for PABC compared to native ABC (15 nM vs 150 nM,
respectively). The improved antiviral potency of PABC compared to ABC is likely
a consequence of the increased intracellular nucleoside 5-Oˊ-triphosphate level,
which is limited by inefficient monophosphorylation of native ABC, as has been
observed previously. In particular, metabolite studies have revealed that the
phosphorylated ABC prodrug is metabolized predominantly to its active
metabolite CBV-TP with no detectable CBV formation [5].
Further optimization of the phosphorylated prodrug into an effective
delivery system for long-term and targeted treatment of HIV was required. One
such strategy would be to encapsulate the phosphorylated ABC prodrug into a
polymeric nanocarrier to prolong drug half-life, improve pharmacodynamics and
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facilitate drug delivery to restricted anatomical reservoirs of HIV-1 persistence
[34, 40]. Lipid–polymer hybrid nanoparticles comprised of a polymer core (e.g.,
PLGA) and lipid/lipid-PEG shell have emerged as versatile carriers due to their
unique composition, possessing both polymeric nanoparticle and liposomal
characteristics [27]. PLGA, a biodegradable and biocompatible FDA approved
polymer, is used to form the biodegradable core matrix, which is then wrapped by
a shell of mixed lipids [41]. The PLGA core matrix encases the therapeutic payload, whereas the mixed lipid monolayer ensures higher encapsulation and
sustained release of the encased drug [42].
In the present work we prepared PABC loaded PLGA/lipid hybrid
nanoparticles to prolong the pharmacological activity of PABC. To demonstrate
that the mixed lipid monolayer provided higher drug encapsulation and sustained
released of loaded cargo a control PLGA formulation without the lipids outerlayer (NAMC) was synthesized using PVA. L-NPABC were slightly larger in size
than NPABC (240 ± 12.0 nm and 208 ± 15.3 nm, respectively) likely due to the
presence of the lipid layer on the surface of the PLGA core [27]. The highly
negative ζ-potential of both nanoformulations provides electrostatic repulsion
between the particles to reduce aggregation, and promote a relatively narrow
size distribution [23]. Drug loading of both nanoformulations was less than 10%,
however drug loading of the L-NPABC particles was slightly higher than for
NPABC particles demonstrating that the benefit of the lipid monolayer shell. The
higher loading can be attributed to formation of lipid vesicles that entrap a small
amount of drug through hydrophobic interaction or hydrogen bonding [27]. L-
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NPABC also provided a more sustained drug release than PABC presumably
due to the presence of a lipid bilayer acting to reduce PABC diffusion from the
PLGA core. In addition to the lipid outer-layer, the PEG shield delays enzymatic
degradation of PLGA matrix [43]. SEM showed that L-NPABC were spherical in
shape with smooth surfaces, and TEM revealed the smooth covering of the outer
lipid layer over the PLGA inner core. These morphologies were similar to those
reported previously for PLGA/lipid hybrid NPs [36].
Mononuclear phagocytes (MP; monocytes, MDM and dendritic cells) have
been shown by our and others studies to serve as drug reservoirs and
carriersThese cells can facilitate drug carriage through their mobility, therapeutic
cargo encasements and ability to home to viral target sites. To determine the
effectiveness of this cell-based system for PABC nanoparticle storage and
delivery human MDM were used to evaluate uptake, antiretroviral efficacy and
subcellular trafficking L-NPABC.

Our results demonstrated that L-NPABC

showed a significantly increased macrophage drug uptake compared to free
PABC that was attributed to higher uptake of the nanoformulation via
phagocytosis [44]. As a consequence of enhanced uptake of PABC, the LNPABC nanoformulations exhibited superior antiretroviral activity compared to
free PABC or native ABC as measured by HIV RT activity and HIV-1 p24 antigen
staining. The antiviral activity was maintained for 15 days after drug loading using
L-NPABC, in contrast to 5 days for free prodrug and no protection for native drug.
Previous work in our laboratory has shown that storage of nanoformulated
antiretroviral drugs in late or recycling endosomal compartments of MDM
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provides protection from drug metabolism in the same subcellular organelles that
harbor HIV, and promotes sustained release of the encased therapeutic cargo.
Co-localization of HIV and drug carrier in similar subcellular organelles boosts
the antiretroviral activity of the drugs [31, 45]. Based upon these studies we
determined whether L-NPABC would be trafficked similarly. Our results showed
significantly higher co-localization of the L-NPABC in recycling endosomal
compartments (Rab11 and Rab14) compared to early endosomes (Rab5) or late
endosomes (Rab7). These results reflected the prolonged antiviral activity of LNPABC nanoformulations compared to native ABC or free PABC. Of importance,
no cytotoxicity was observed in MDM at the concentration of L-NPABC
nanoformulations or PABC used for these studies.
These results suggested that sustained drug delivery and improved
antiretroviral activity could be expected in vivo using L-NPABC. To determine
whether L-NPABC could attenuate viral replication in vivo an acute HIV infection
humanized mouse model was used. Hu-PBL-NSG mice were treated
subcutaneously with L-NPABC or native ABC at equivalent doses, 24 h prior to
HIV-1ADA infection. Ten days later HIV infection was determined using
immunohistochemistry and RT-PCR. Our data demonstrated that mice treated
with nanoformulated PABC showed less HIV-1p24 antigen in spleen compared to
HIV positive controls and animals treated with ABC. ABC treatment did not
provide protection from viral infection. Since, HIV-1 infection results in a gradual
decline of CD4+ T cells in hu-PBL-NSG mice [37-39], we determined CD4+ and
CD8+ T cell populations in the spleen and blood. Mice that were treated with free
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ABC or not treated (HIV+ control) showed a significant loss in CD4+ T cells in
spleen. In contrast, in mice treated with L-NPABC depletion in CD4+ T cells was
prevented. In addition the CD4+ /CD8+ T-cell ratios of L-NPABC treated mice
were significantly higher than in mice treated with free ABC or not treated.
However, there were no significant differences in CD4+ /CD8+ T-cell ratios in
blood between HIV-infected and drug treated, HIV-infected and non-drug treated
and non-infected control mice (data not shown). This could be related to the
higher numbers of T-cells in the spleen, a viral reservoir compared to the blood in
addition to the limitations in immune restoration within the hu-PBL-NSG HIV mice
model [40]. Such limitations could be overcome by using CD34+ hematopoietic
stem cell humanized mice, a chronic model of HIV infection [40]. As an additional
measure of HIV replication, we determined HIV-1gag RNA levels in spleen by
RT-PCR analysis.

We observed that L-NPABC treatment suppressed HIV-1

replication to a greater extent compared to free drug or no treatment. These
findings together suggest that the lipid coating over the PLGA core provides
sustained release of PABC to prolong therapeutic activity.
3.5. CONCLUSIONS
We demonstrate that a phosphorylated prodrug of ABC (PABC) has
improved antiretroviral activity over the native drug. The improved lipophilicity of
PABC facilitated the encasement of the prodrug into PLGA nanoformulations with
reasonable drug loading. Notably, coating the prodrug within a lipid-modified
polymer matrix provided improved MDM uptake, retention and antiretroviral
efficacy. Nanoformulations localized to recycling endosomal compartments in
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macrophages as has been previously observed for nanoformulated atazanavir
and ritonavir [31]. Of importance, in a humanized mouse model of HIV infection,
antiretroviral activity of PABC was extended over 10 days when encased into
lipid-PLGA following a single SC dose.
3.6 SUMMARY
The quest amongst academics and pharmaceutical scientists in HIV/AIDS
research to transform short-acting antiretroviral drugs into long-acting reservoir
targeted medicines is substantive as the field aims to improve compliance while
reducing viral resistance and toxicity. A means to achieve this end rests in
manufacture of nanoformulated phosphoramidate prodrugs for nucleoside
reverse transcriptase inhibitors as it would do all that as well as improve
antiretroviral responses. Thus, we encapsulated phosphorylated abacavir
(PABC) into mixed polymeric and lipid excipients to facilitate available
intracellular nucleoside 5-Oˊ-triphosphates by bypassing rate-limiting parent drug
monophosphorylation. We also reasoned that a long-acting nanoformulated
PABC (NPABC) would improve ABC pharmacodynamics (PD) profiles. Herein,
PABC was successfully synthesized then characterized by 1H-NMR and FTIR
spectroscopy. PABC antiretroviral activities were compared to native ABC by
assessment of its half maximal effective concentration50. A PABC was
incorporated into a PLGA-lipid nanoformulation then assessed for structural
stability, morphologic integrity, cytotoxicity, and attenuation of HIV-1 replication.
The latter two were determined by viral p24 staining and reverse transcriptase
activity. Pharmacokinetic profiling was performed in Balb/C mice after a singular
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intramuscular

injection.

Preliminary

pharmacodynamic

evaluation

was

determined in human peripheral blood lymphocyte (hu-PBL) reconstituted
NOD/scid-IL-2Rgc mice-infected with HIV-1ADA. Results demonstrated that
antiretroviral responses were operative for ten days after single administration of
in monocyte-derived macrophages and 10 days NPABC activity in virus-infected
mice. These data, taken together, support the idea that antiretroviral responses
could be achieved through intracellular delivery of NPABC. The PLGA-lipid
matrix protected the drug from rapid elimination over 10 day’s period.
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Figure 3.1. Synthesis of PABC. PABC was synthesized in two steps as
illustrated at a final yield of 62%; Phoshporochloridate moiety was synthesized
using phenyl dichlorophosphate and L-alanine methyl ester (step 1); followed by
its coupling with ABC (step II) using tert-butylmagnesium chloride as base in
THF.
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Figure 3.2. Characterization of PABC. The purified PABC was characterized
using (A) the 1H-NMR spectroscopy, which dictated the presence of a multiplet at
7.1-7.4 ppm corresponding to five protons from the benzene ring of the
derivatizing phosphate moiety. The singlet at 3.70 ppm and two doublets at 1.38
ppm represent the three methyl ester protons and gamma protons from alanine
on the phosphate group. (B) Peaks at 1739 cm-1 and 1208 cm-1 in the PABC
FTIR spectrum correspond to carbonyl (C=O) and phosphate (P=O) stretching of
the phosphochloridate moiety, whereas the peak at 1588 cm -1 in ABC and PABC
spectra corresponds to CH2 stretching of aromatic ring.
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Figure 3.3. Antiviral activity of ABC and PABC against HIV-1ADA in human
monocyte derived macrophages (MDM). MDM were exposed to various
concentrations of ABC or PABC for 60 min, followed by challenge with HIV-1ADA
at a multiplicity of infection of 0.01 infectious viral particles /cell for 4 h. HIV
reverse transcriptase (RT) activity was measured on day 10 post infections. The
EC50 of PABC (~15 nM) was decreased about 10 –fold compared to native ABC
(~150 nM)
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Figure 3.4. Synthesis and characterization of PABC loaded PLGA
nanoparticles. (A) Drug encased nanoparticles of mixed lipid outer shell and
biodegradable PLGA inner core were prepared using the single-emulsion solvent
evaporation method. (B) PABC encased PLGA hybrid nanoparticles were of
around 200nm in size as of measured by dynamic light scattering.
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Figure 3.4. Morphological analysis of drug PLGA nanoparticles. Morphology
of nanoparticles was measured using (A) SEM and (B) TEM analysis. Images of
L-NPABC revealed morphology and surface coating of lipids respectively. The
size of nanoparticles as measured by SEM and TEM are in accordance with DLS
measurement.
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Figure 3.5. In vitro drug-release profile of PABC from PLGA matrix. The in
vitro drug release of PABC was measured in Phosphate buffer (pH 7.4) at 37 °C.
The cumulative drug PABC release from L-NPABC were measured and
compared with NPABC (PLGA particles without lipid covering). At each time point
100 µL of release media was collected with equal replacement of fresh media.
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Figure 3.6. MDM uptake and antiretroviral efficacy of ABC, PABC and LNPABC. (A) Drug and nanoformulation uptake was determined in MDM over 24
h following treatment with 100 µM PABC or L-NPABC. Antiretroviral activity was
determined in MDM treated with 100 µM native ABC, free PABC or
nanoformulated PABC for 8 h, then infected with HIV-1ADA (MOI 0.1) at 1, 5, 10 or
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15 days following drug loading. HIV replication was determined 10 days after
infection by (B) HIV RT activity and (C) HIV p24 staining. For uptake studies,
statistical differences were determined using Student’s t-test (**P < 0.001 and *P
< 0.05).
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Figure 3.7. Subcellular localization of nanoformulated PABC in MDM. MDM
cultured in 8 well Lab-Tek II CC2 chamber slides were treated with 100 μM
fluorescein labeled L-NPABC for 8 h then fixed and stained with antibodies to
Rab 5, 7, 11 and 14. (A) Co-localization is observed as a yellow punctate pattern
throughout the cytoplasm and perinuclear cell regions in merged images of red
NPs and green subcellular compartments. (B) Percent fluorescence overlap was
quantitated using ImageJ software, and JACoP plug-in. Statistical differences
were determined using Student’s t-test (**P < 0.001 and *P < 0.05).
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Figure 3.8. Antiviral activity of L-NPABC in hu-PBL-NSG mice. (A) Schematic
illustration of ddIn vivo study; antiretroviral response comparing nanoformulated
PABC to free ABC was performed in HuPBL reconstituted NOD/scid-IL-2Rgc
(NSG huPBL) mice-infected with HIV-1ADA. Mice were subcutaneously injected
with 100 mg/kg of ABC or equivalent dose using L-NPABC on day 1. Mice were
infected with HIV-1ADA one day later and scarified on day 10 post infection. (B)
Spleens were collected on day 10 after infection, then sectioned and
immunostained with antibodies specific for HLA-DR or HIV-1p24, and visualized
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by DAB. (C) Number of HIV-1p24+ cells per section were counted and expressed
as percent of HLA-DR+ cells. (D) Immune profiles (CD4+/CD8+ T cell ratios)
were determined in spleen cells, and (E) HIV1gag RNA copies were measured in
spleens cells and normalized to human CD45 expression as a human cell
marker. Data are expressed as mean ± SEM, and considered significant at p <
0.001 by student t-test.
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Table 3.1. Physicochemical characteristics of NPABC and L-NPABC. Data
represent mean ± SD, n= 3.
Formulations

Particle

PDI

Zeta

Drug

NPABCb

Potential
Loading
208
± 17
0.18 ± 0.05 -17.6
± 1.7
4.5
± 0.7
Size(nm)
L-NPABC
240 ± 10
0.22 ± 0.03 -21.6 ± 2.7
7.5 ± 0.4
a
a
(mV)
Drug loading efficiency = (mg of PABC encapsulated in NP/ mg (%)
of lyophilized
c

NP)×100.
b

NPABC = PABC-loaded within PLGA matrix

c

L-NPABC= PABC-loaded within PLGA matrix and coated with DSPC, DSPG

and DSPE-PEG2k
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CHAPTER 4. DEVELOPMENT AND
CHARACTERIZATION OF A LONG-ACTING
NANOFORMULATED ABACAVIR (ABC) PRODRUG
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4.1. INTRODUCTION
Treatment of human immunodeficiency virus (HIV) infection mandates
early and lifelong treatment with combination antiretroviral therapy (cART) [1].
One impediment in reaching successful clinical outcomes is lack of adherence to
cART drug regimens that serve to sustain reductions in viral load and maintain
CD4+ T lymphocyte numbers [2, 3]. Maintaining cART drug levels is essential to
protect susceptible cell populations and enable sustained antiviral responses to
preclude the development of viral resistance [1]. Lack of achievement of LC/MS-l
treatment outcomes rests in the inabilities of drugs to specifically target viral
reservoirs [4]. These include gut-associated lymphoid tissue (GALT), lymph
nodes, spleen, the central nervous system (CNS), and specifically central
memory lymphocytes and myeloid cells contained within the lymphoreticular
tissues [5-7]. Limitations in drug bioavailability have affected therapeutic
outcomes [8]. All can lead to the perpetuation of viral sanctuaries and accelerate
cART failures [9, 10]. We posit that the development of long-acting viral reservoir
targeted nanoformulated ART (nanoART) can overcome such limitations while
reducing drug toxicity and metabolism, improving drug targeting, and facilitating
slow release of drug cell-carried cargos. These ultimately serve to improve
antiretroviral drug pharmacokinetics (PK) and pharmacodynamics (PD) [11-15].
To such ends, our laboratory has pioneered the development of nanoART [1619]. Our nanoformulations show further improvements in design through ligand
surface engineering [13, 19] serving to facilitate uptake into virus target cells.
Mononuclear phagocytes (MP; monocytes, macrophages and dendritic cells)
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serve as drug carriers. These cells facilitate drug carriage through their mobility,
rapid delivery, cargo encasements, and abilities to deploy drug to viral target
tissues [20]. To such ends, the ability of nanoART to home drug depots to viral
reservoirs represents notable advantages over conventional therapy [21]. This
explains the need for an interdisciplinary program serving to encapsulate
antiretroviral drugs into polymeric nanoparticles for MP drug delivery and
enabling PK and PD testing [16, 17, 19, 22].
An obstacle toward success has been the difficulty in formulating the
many available hydrophilic antiretroviral drugs into nanoparticles for parenteral
administration. Thus, a platform was constructed to convert the drug abacavir
(ABC) into a hydrophobic compound through esterification using myristic acid. Of
interest, fatty acid analogues of myristic acid can inhibit N-myristoyltransferase,
an enzyme that catalyzes myristoylation which is needed for activity of several
proteins involved in the life cycle of HIV [23-27]. With this in mind, myristoylated
ABC (called, MABC) was synthesized then formulated into nanosuspensions.
This enabled the formation of hydrophobic drug crystals that were then placed
into poloxamer-coated nanoparticles. Improved antiretroviral activity was
observed for the modified ABC. Pro-longed antiretroviral activity was realized
with the establishment of drug depots in Rab endosomes. Prolonged drug MP
carriage and PK supports the opinion that MABC holds promise to extend the
drug armamentarium for HIV/acquired immune deficiency syndrome (AIDS)
therapy.
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4.2. MATERIALS AND METHODS
4.2.1. Chemicals
ABC sulfate, myristic acid, poloxamer 407 (P407), folic acid (FA), and
CF633-succinimidyl ester were purchased from Sigma-Aldrich (St. Louis, MO,
USA). ABC sulfate was converted into free-base using sodium bicarbonate. The
chemical reactions were performed under a dry argon atmosphere. Flash
chromatography was performed using 32-63 μm flash silica gels from Dynamic
Adsorbents, Inc. (Norcross, GA, USA). Reactions were followed by thin-layer
chromatography on precoated silica plates (250 μm) F-254 from SiliCycle Inc
(Quebec City, QC, Canada). The compounds were visualized by UV
fluorescence or by staining with ninhydrin or KMnO 4 stains. High performance
liquid chromatography (HPLC) grade methylene chloride, acetonitrile, methanol,
dimethylformamide (DMF), LC/MS-grade water, and phosphate-buffered saline
(PBS) were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Rabbit antihuman antibodies to LAMP1, Rab7, Rab11, Rab14, and AlexaFluor 488
conjugated goat anti-rabbit IgG were purchased from Santa Cruz Biotechnology
(Dallas, TX, USA). Folate-modified P407 (FA-P407) and CF633-modified P407
were synthesized as described [20].
4.2.2. MABC Synthesis
ABC (3.49 mmol, 1 equivalent) was dried by azeotroping from anhydrous
pyridine, then suspended in anhydrous DMF and cooled to 0 °C under argon.
Selective silylation of the 5-hydroxyl group of ABC was conducted by adding tertbutyldimethylsilyl chloride (TBSCl) (4.18 mmol, 1.2 equivalents) and imidazole
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(5.23 mmol, 1.5 equivalents) to the suspension with continuous stirring for 16 h
after which the desired silylated product was isolated by flush chromatography
purification and characterized by proton nuclear magnetic resonance ( 1H-NMR)
spectroscopy. The amino group in the silylated ABC was then protected by
reacting with methoxytriphenyl chloride (DMTr-Cl) (5.05 mmol, 2.2 equivalents) in
anhydrous pyridine solvent to yield orthogonally protected ABC. Selective
cleavage of the silyl group was achieved using tetra-n-butylammonium fluoride
(4.87 mmol, 2.5 equivalents) to afford the free primary alcohol that was coupled
with

myristic

acid

(3.36

mmol,

2

equivalents)

using

[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,

5-b]pyridinium

hexafluorophosphate

equivalents)

(HATU)

(3.63

mmol,

2.2

13-oxid

and

N,N-

diisopropylethylamine (DIEA) (8.26 mmol, 5 equivalents) in DMF. Finally,
cleavage of DMTr using trifluoroacetic acid produced MABC after purification; 1HNMR spectrum specifics: Rf 0.38 (9:1 CH2Cl2/MeOH); 1H-NMR (500 MHz, CD3OD)
δ 0.60-0.67 (br, 2H), 0.82-0.94 (m, 5H), 1.21-1.50 (br, 23H), 1.69-1.80 (m, 3H),
2.60-2.74 (br, 1H), 2.82 (t, J = 8.6 Hz, 1H), 2.85 (t, J = 8.6 Hz, 1H), 2.96-3.12 (br,
2H), 3.61 (dd, J = 5.3, 10.8 Hz, 1H), 3.68 (dd, J = 5.3, 10.8 Hz, 1H), 5.77-5.80
(br, 1H), 5.92-5.98 (m, 1H), 6.16-6.33 (m, 1H), 8.01 (s, 1H).
4.2.3. Antiretroviral Activity of MABC
Human peripheral blood monocytes were obtained from HIV-1 and -2 and
hepatitis seronegative donors and purified using counter-current centrifugal
elutriation

[28].

The

monocytes

were

cultured

and

differentiated

into

macrophages (MDM) using DMEM with 10% heat-inactivated pooled human
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serum, 1% glutamine, 50 μg/ml gentamicin, 10 μg/ml ciprofloxacin and 1000 U/ml
MCSF for 7-10 days [29]. The antiviral activity of native drug and prodrug against
HIV-1 was determined in human MDM at day 10 post-infection as described [30].
Briefly, MDM were exposed to various concentrations of ABC or MABC for 60
min followed by challenge with HIV-1ADA at a multiplicity of infection (MOI) of 0.01
infectious viral particles/cell. After 4 h of incubation, cells were washed three
times with PBS to remove excess virus followed by incubation with the same
concentration of drug used before infection. Cells were cultured for an additional
10 days with half media changes every other day with equivalent replacement of
drug containing media. Supernatants were collected at day 10 after viral
infection, and the level of viral replication was determined by HIV reverse
transcriptase (RT) activity [31].
4.2.4. Nanoformulated MABC (NMABC)
Crystalline MABC was encased in poloxamer P407 (NMABC) using highpressure homogenization (Avestin EmulsiFlexC3; Avestin, Inc., Ottawa, ON,
Canada) [16, 19]. Briefly, a suspension of 1% (w/v) MABC and 0.5% (w/v) P407
in 10 mM HEPES buffer (pH 5.5) was premixed overnight at room temperature to
generate

drug

containing

polymeric

micelles.

Suspensions

were

then

homogenized by high-pressure homogenization (20,000 PSI) until the desired
particle size of ~250 nm was achieved. Folate-targeted nanoformulation (FANMABC) was prepared in an analogous manner from a premix of 0.5% polymer
as FA-P407 and P407 (60:40% w/w) [20]. Crude nanoformulations were purified
by differential centrifugation at 5000 × g for 5 min to remove aggregated
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particles. Further centrifugation at 20,000 × g for 20 min was used to remove the
free MABC and polymeric micelles. Purified nanoparticle pellets were
resuspended in 10 mM HEPES buffer (pH 5.5) for physicochemical
characterization and for in vitro and in vivo studies. To prepare CF633-P407
labeled nanoformulations, CF633-P407 and P407 were dissolved in methanol at
a weight ratio of 1:5 [20, 32]. Methanol was then evaporated to generate a thin
polymer film that was rehydrated using 10 mM HEPES buffer (pH 5.5) to yield a
final excipient concentration of 0.5% (w/v). To this polymer solution, free MABC
was added at a 1% (w/v) ratio. The suspension was protected from light and
premixed at room temperature for 16 h. The suspension was homogenized and
purified as described earlier for unlabeled formulations. CF633-labeled folatetargeted nanoformulations were prepared similarly where CF633-P407, P407,
and FA-P407 were dissolved in methanol at a weight ratio of 1:2:2.
4.2.5. Physicochemical Characterizations of MABC and its Derivatives
MABC was characterized using 1H-NMR and Fourier transform infrared
(FTIR) spectroscopy. 1H-NMR spectra were recorded on a Varian INOVA 500
mHz spectrometer (Varian, Inc., Palo Alto, CA, USA). 1H-NMR data is reported in
ppm downfield from trimethylsilyl as an internal standard. FTIR spectra were
recorded using a Spectrum Two UATR-Two FTIR spectrometer (PerkinElmer,
Inc. Waltham, MA, USA). Nanoformulations were characterized for their particle
size, polydispersity index (PDI), and zeta potential by dynamic light scattering
(DLS) using a Malvern Zetasizer, Nano Series Nano-ZS (Malvern Instruments,
Inc., Westborough, MA, USA). The morphology of the nanoformulations was
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examined by scanning electron microscopy (SEM) using a Hitachi S4700 fieldemission scanning electron microscope (Hitachi High Technologies America,
Inc., Schaumburg, IL, USA) [16]. Stability of the nanoformulation suspensions
was assessed at room temperature (25 °C) and at 4 °C for a period of 8 weeks
by measuring particle size and PDI by DLS. Drug loading, i.e. the weight
percentage

of

MABC

encapsulated

in

a

given

mass

of

lyophilized

nanoformulation, was determined by UPLC-MS/MS (tandem mass spectrometry).
To determine drug concentration in purified nanosuspensions, an aliquot of the
nanosuspension was extracted using methanol and analyzed by UPLC-MS/MS
[20].
4.2.6. Nanoparticle MDM Uptake and Retention
Uptake and retention of nanoformulations were determined in human
MDM [16, 33]. Briefly, MDM were treated with nanoformulations at a
concentration of 100 µM MABC. Cell uptake was assessed at different time
points without any media changes. At each time point, adherent MDM were
washed three times with 1 ml of PBS, scraped into 1 ml of fresh PBS and
pelleted by centrifugation at 950 x g for 8 min. The cell pellet was reconstituted in
200 µl methanol and probe sonicated followed by centrifugation at 20,000 x g for
20 min. The supernatant was analyzed for drug content using UPLC/MS-MS.
To determine involvement of folate receptors (FOLR) in MDM uptake of
the folate-targeted nanoformulation, cells were pre-incubated with 50 µM free
folic acid for 60 min prior to treatment with 100 µM FA-NMABC. For cell retention
studies, MDM were treated with 100 µM of nanoformulated MABC for 8 h; cells
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were then washed with PBS to remove free drug or unincorporated
nanoparticles, followed by further incubation in MCSF-free medium without
nanoformulation. At days 1, 5, 10, and 15, cells were washed, collected, and
analyzed for drug content as described for uptake studies. Cell viability was
determined using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) [16]. Briefly, MDM were treated with 10, 50, 100, and 200 µM NMABC or
FA-NMABC for 24 h. The adherent cells were washed with PBS, and 200 µl of
MTT working solution (0.5 mg/ml diluted in MCSF free media) was added to the
cells followed by incubation at 37 °C for 30 min and washing with PBS. DMSO
(200 µl/well) was added to the cells and incubated for 5 min at 25 °C. The
absorbance at 490 nm was measured using a SpectraMax M3 Microplate reader
(Molecular Devices, Sunnyvale, CA, USA).
4.2.7. Antiretroviral Activity of MABC Nanoformulations
MDM were treated with 100 µM MABC using free MABC or
nanoformulations for 8 h. The cells were washed with PBS to remove excess free
drug and nanoparticles. The MDM were challenged with HIV-1ADA at a MOI of
0.01 infectious viral particles /cell for 18 h on day 1, 5, 10, and 15. Progeny virion
production was measured by RT activity in culture medium [31]. HIV-1 p24
protein expression was assessed in adherent cells [32]. The cells were washed
with PBS and fixed with 4% paraformaldehyde (PFA) for 15 min at room
temperature. The cells were blocked using 10% bovine serum albumin (BSA)
containing 1% Triton X-100 in PBS for 30 min at room temperature. Following
blocking, cells were incubated with HIV-1 p24 mouse monoclonal antibodies
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(1:50; Dako, Carpinteria, CA, USA) for overnight at 4 °C, followed by 1 h
incubation at room temperature. HRP-labeled polymer anti-mouse secondary
antibody (Dako EnVision® System; Dako, Carpinteria, CA, USA) was added (one
drop/well). Hematoxylin (500 µl per well) was added to counterstain the nuclei,
and images were captured using a Nikon TE300 microscope with a 20X
objective.
4.2.8. MABC Nanoparticle Subcellular Localization
To determine subcellular localization of nanoformulated MABC, human
monocytes were cultured in an 8 well Lab-Tek II CC2 chamber slide at a density
of 5 X 105 cells/well and differentiated into macrophages as described previously
[20]. MDM were treated with 100 µM of MABC using CF633-labeled NMABC or
FA-NMABC for 8 h, washed with PBS, fixed, and stained using subcellular
compartment antibodies [20, 32]. Briefly, cells were fixed with 4% PFA for 30 min
at room temperature, permeabilized using 5% Triton-X in PBS for 15 min, and
blocked with 5% BSA and 0.1% Triton-X in PBS. The cells were then incubated
overnight at 4 °C for 1 h at room temperature with primary antibody (1:25 dilution
in 5% BSA and 0.1% Triton-X in PBS) for respective endocytic compartments:
late endosomes (Rab 7; sc-10767), recycling endosomes (RAB11 and Rab14;
sc-9020 and sc98610), and lysosomes (LAMP1; sc-5570). The cells were
washed extensively using 0.1% Triton-X in PBS and subsequently were
incubated with secondary antibody conjugated with AlexaFluor 488 for 60 min at
room temperature. The cells were covered with ProLong Gold anti-fade reagent
with DAPI I (4,6-diamidino-2-phenylindole), cover slipped, and imaged with an
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LSM 510 microscope using a 63X oil lens using an LSM 510 confocal
microscope (Carl Zeiss Microimaging, Inc., Dublin, CA, USA).
4.2.9. PK Studies
Animal PK studies were conducted in accordance with the University of
Nebraska Medical Center Institutional Animal Care and Use Committee (IACUC).
Male Balb/cJ mice (Jackson Labs, Bar Harbor, ME, USA) were maintained on a
folate deficient diet (Harlan Teklad TD.00434; Harlan Laboratories, Inc.,
Indianapolis, IN, USA) for two weeks prior to treatment and throughout the study.
Mice were injected intramuscularly (IM) with 50 mg/kg ABC equivalents using
native ABC, NMABC, or FA-NMABC in PBS. On days 1, 3, 5, 7, 9, 12, and 14
after drug treatment approximately 50 µl blood was collected by cheek bleeding,
and immediately 40 µl was added into 1 ml of acetonitrile for drug analysis.
Internal standard (IS; 10 µl) was added to each sample and consisted of 0.665
µg/ml d4-ABC, and 0.5 µg/ml lopinavir. Samples were centrifuged at 17,000 x g
for 10 min, and supernatants were dried using a ThermoScientific Savant Speed
Vacuum (ThermoScientific, Waltham, MA, USA), reconstituted in 100 µl of 80%
v/v methanol in LC/MSUPLC-MS/MS analysis. Thirty µl of the reconstituted samples were diluted with
50 µl water for ABC UPLC-MS/MS analysis. Final concentrations for both d4-ABC
(IS for ABC) and lopinavir (IS for MABC) were 50 ng/ml. Standard curves of ABC
or MABC were prepared similarly, in blood collected from control mice in the
range of 0.35-3500 ng/ml and 0.125-1250 ng/ml, respectively. A Waters
ACQUITY H-class UPLC system (Waters, Milford, MA, USA) connected to a
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Waters Xevo TQS-micro mass spectrometer with electrospray ionization (ESI)
source was used for drug quantitation. Chromatographic separation of 10 µl ABC
sample injections was achieved on an ACQUITY UPLC CSH C18 column (1.7
µm, 100 mm x 2.1 mm) using a 13 min gradient of mobile phase A (7.5 mM
ammonium bicarbonate in grade water, adjusted to pH 7 with glacial acetic acid)
and mobile phase B (100% LC/MS- grade methanol) at a flow rate of 0.25
ml/min. The initial mobile phase composition was 10% B for the first 2.5 min and
was gradually increased to 95% B in 6.5 min and held constant for 1.5 min.
Mobile phase B was then reset to 10% in 0.45 min, and the column was
equilibrated for 2.25 min before the next injection. MABC chromatographic
separation was achieved using the same CSH C18 column and mobile phases
but with a 16 min isocratic method using 81% mobile phase B and flow rate of
0.3 ml/min. ABC and MABC were detected at a cone voltage of 8V and 16 V,
respectively, and a collision energy of 16 V and 30 V, respectively, in the positive
ionization mode. Multiple reaction monitoring (MRM) transitions used for ABC,
MABC, d4-ABC, and lopinavir were 287.14 > 191.00, 497.18 > 191.07, 291.14 >
79.02, and 629.18 > 447.2 (m/z) respectively. Spectra were analyzed and
quantified by MassLynx software version 4.1. All calculations were made using
analyte peak area to internal standard peak area ratios.
4.2.10. Statistical Analyses
Drug uptake and retention data were analyzed by one-way analysis of
variance (ANOVA) and Student's t-test using GraphPad Prism software
(GraphPad Software, Inc., La Jolla, CA, USA). Confocal images were analyzed
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as percent overlap using ImageJ software with JACoP plugin to quantify the
amount of overlap between labeled nanoparticles and labeled endocytic
compartments. Differences of mean percent overlap between nanoformulations
were analyzed using Student's t-test. Experiments were performed three times
unless otherwise specified. Animal studies were conducted with five animals per
treatment group. Statistical analysis was performed by 2-way ANOVA and
Bonferroni’s Multiple Comparison test. Results are expressed as mean ±
standard error of mean. Results were considered significant at a p value < 0.05.
4.3. RESULTS
4.3.1. MABC Synthesis and Characterization
In its native form, ABC has restricted intracellular and tissue penetrance
[30, 34]. Its hydrophilic nature also poses challenges for nanoformulation
preparations. To facilitate encapsulation of ABC into a poloxamer-stabilized
nanosuspension, MABC, a hydrophobic prodrug of ABC, was synthesized. This
was accomplished through derivatization of the native compound with a
cleavable fatty acid ester (Figure 4.1). Covalent linkage of myristic acid to the 5’O-hydroxyl group of ABC was confirmed by nuclear magnetic resonance, Fourier
transform infrared spectroscopy and tandem mass spectrometry (1H-NMR, FTIR
and MS/MS). Specifically, the triplet at 2.36 ppm in the 1H-NMR spectrum of
MABC represents two fatty acid methylene protons adjacent to the carbonyl
group linked to ABC, while the broad multiplet signal in the region of 1.21-1.50
ppm of the spectrum corresponds to 20 hydrogens of the repeating methylene
units of the fatty acid chain (Figure 4.2A). This was confirmed by comparing FTIR
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spectra of MABC to that of native ABC and myristic acid (Figure 4.2C). The
presence of alkane stretching (CH2-CH2) peaks at 2915 cm-1 and 2850 cm-1 in
the FTIR spectrum of MABC confirmed that the alkane chain of the derivatizing
fatty acid (2913 and 2847 cm-1) with the parent drug occurred. The peaks at 1595
cm-1 in MABC and 1588 cm-1 in the ABC FTIR spectra corresponded to CH2
stretching of the native aromatic ring. Peaks at 1673 and 1696 cm -1 in MABC and
myristic acid corresponded to C=O fatty acid attachments. The peak at 1033 cm -1
and 1030 cm-1 in ABC and MABC spectra corresponded to NH2 broadening of
the parent compound. Infusion into a Waters Xevo TQS micro mass
spectrometer confirmed a molecular mass ion of 496.2, which corresponds to
ABC with one myristoyl group (data not shown).
4.3.2. Antiretroviral Activity of MABC
The antiretroviral activities of MABC and native drug were compared in
MDM. Various concentrations of ABC or MABC bracketing the EC 50 for ABC
were added to MDM prior to and continued with HIV-1ADA infection [30].
Antiretroviral activity was determined by measuring RT activity in culture fluids
collected 10 days after drug treatment and infection. The antiviral activity of
MABC as determined by the EC50 for viral suppression was comparable to that of
the parent drug (̴ 100 µM) (Figure 4.3).
4.3.3. Preparation and Physicochemical Characterization of the NMABC
Poloxamer nanoformulations of MABC were prepared by high-pressure
homogenization as previously described [16, 18]. Nanoparticles in suspension
were characterized by DLS and SEM. The physicochemical parameters of
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NMABC and FA-NMABC nanoparticles were similar. The size, PDI, and zeta
potential of NMABC nanoparticles were 160 ± 10 nm, 0.2 ± 0.1, and −27.5 ± 2.5
mV, respectively. Similarly, the size, PDI and zeta potential of FA-NMABC
nanoparticles were 170 ± 12 nm, 0.15 ± 0.04, and −33.7 ± 3.7 mV, respectively.
Relatively low PDI values displayed by the two nanoformulations indicated a
narrow particle size distribution within the suspensions. Morphologically both
NMABC and FA-NMABC were observed to be cylindrical rods of 200 nm in size
as determined by SEM, correlating with particle size determined by DLS (Figure
4.4A & B). The stability of nanoformulations over time and temperature was
assessed by measuring the NMABC particle sizes over a period of 8 weeks at 4
°C and 25 °C. During this time, the size and PDI did not change significantly at
either of the two temperatures (Figure 4.4C & D), an indication that the
nanoformulations remained stable for at least two months. Drug loading for
NMABC and FA-NMABC nanoformulations was found to be 62 ± 1.5 and 65 ±
2.4% respectively. Lyophilized formulation powders were also characterized by
magnetic resonance spectroscopy in DMSO. The presence of a singlet at 3.7
ppm in the 1H-NMR spectrum of the formulation corresponds to the repeating
methylene- units (next to oxygen) of the polymer. Peaks corresponding to the
myristoylated prodrug protons were also evident in the formulation spectrum.
4.3.4. Nanoformulated Drug Uptake and Retention
To determine whether FOLR targeting would enhance MDM uptake and
consequently retention of MABC, MDM were treated with 100 µM MABC using
NMABC or FA-NMABC for up to 8 h. MDM uptake of nanoformulated MABC
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increased over time and reached a maximum at 8 h. As shown in Figure 4.6A, an
up to 2.5-fold increase in uptake was observed for FA-NMABC compared to
NMABC. Cell MABC concentrations for FA-NMABC nanoformulations were 5.12
± 0.2, 11.3 ± 0.3, 19.07 ± 1.2, and 24.7 ± 1.5 µg/10 6 cells at 1, 2, 4, and 8 h,
compared to 2.1 ± 0.1, 3.5 ± 0.2, 8.6 ± 1.2, and 11.3 ± 1.5 µg/10 6 cells for
NMABC formulations at the same time points. In order to deduce whether
improved uptake of FA-NMABC was mediated by the FOLR, MDM were
incubated with excess free folic acid (50 µM) prior to treatment. As shown in
Figure 4.6A, blocking FOLR with excess folic acid decreased FA-NMABC uptake
to levels similar to that of NMABC. Substantial (1.5 to 3 orders of magnitude)
differences were observed in the extent of MABC retention in MDM over 15 days
with FA-NMABC compared to NMABC, reflecting the initial enhanced uptake
using the folate-targeted nanoformulation (Figure 4.6B). The uptake and
retention of MABC using FA-NMABC was significantly greater than that observed
for NMABC (Student’s t-test, **P < 0.001). The concentration of nanoformulations
used (100 µM) did not induce cell toxicity as determined by the MTT assay (data
not shown).
4.3.5. Antiretroviral Activities of Nanoformulated MABC
To determine whether improved hydrophobicity of MABC and subsequent
improved uptake and retention in MDM using MABC nanoformulations would
translate into improved antiretroviral activity, MDM were treated with 100 µM
native ABC, free MABC, NMABC or FA-NMABC for 8 h. Following treatment,
MDM were challenged with HIV-1ADA at an MOI of 0.1 on days 1, 5, 10, and 15
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post-treatment. Decreased RT activity in infectious supernatants collected on day
10 post-infection revealed that FA-NMABC exhibited enhanced antiretroviral
activity compared to NMABC or free MABC (Figure 4.7A). RT activity was not
decreased in supernatants collected from MDM treated with native ABC,
suggesting either no uptake or rapid metabolism of the native drug. However,
native ABC suppressed HIV RT activity by 100 and 95% when cells were treated
12 and 24 h after HIV-1 exposure (data not shown). HIV replication using FANMABC was suppressed by 100 ± 2.3% at days 1 and 5 and by 88 ± 3.4 % and
70 ± 2.5% at days 10 and 15; whereas, NMABC suppressed viral replication by
100 ± 1.5%, 78 ± 1.7%, 72 ± 3.5%, and 52 ± 4.5% at days 1, 5, 10 and 15,
respectively. Minimal or no inhibition was achieved using free MABC (Figure
4.7A). RT activity was cross-validated by evaluating HIV-1 p24 antigen
expression in adherent MDM 10 days post-infection. MDM treated with free
MABC or NMABC showed increased viral infection from days 1 to 15, as
observed by the intensity of brown staining of p24 antigen; whereas, minimal to
no p24 antigen was detected in MDM treated with FA-NMABC measured at all
time points (Figure 4.7B).
4.3.6. Subcellular Nanoparticle Localizations
Sub-cellular localization of the nanoformulations taken up by MDM was
assessed using confocal microscopy. MDM were treated with 100 µM CF633labeled NMABC or FA-NMABC for 8h. Physicochemical parameters for CF633labeled nanoformulations were similar to that of unlabeled nanoformulations
(data not shown). After incubation, cells were washed, fixed, and stained with
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antibodies to endosomal compartments as described [20, 32]. Rab7 antibody
identified the late endosomal compartments, Rab11 and Rab14 antibodies
identified compartments involved in recycling, and LAMP1 (lysosomal-associated
membrane protein 1) antibody identified the lysosomal compartments. Colocalization was seen as a yellow punctate pattern throughout the cytoplasm and
perinuclear cell regions in the merged images of red nanoparticles and green
compartments.

For

both

nanoformulations

co-localization

was

found

predominantly in recycling endosomes compared to late endosomal and
lysosomal compartments (Figure 4.8A). Percent overlap between endosomal
compartments and nanoformulations, as determined using ImageJ software and
JACoP plug-in, showed greater co-localization of nanoparticles with recycling
endosomal compartments (46 ± 2.4% and 62 ± 1.5%, Rab11 and Rab14 for
NMABC; 70 ± 1.7 and 79 ± 4.3, Rab11 and Rab14 for FA-NMABC) than with
lysosomal and late endosomal compartments (27 ± 1.8 % and 36 ± 2.3 %,
LAMP1 and Rab7 for NMABC; 34 ± 3.2 and 64 ±2.8, LAMP1 and Rab7 for FANMABC) (Figure 4.8B). FA-NMABC exhibited significantly greater co-localization
with all compartments compared to NMABC (*P < 0.05).
4.3.7. PK Studies
To determine whether improved hydrophobicity and encapsulation of
MABC into poloxamer nanoformulations would translate into sustained blood
ABC drug levels in vivo, mice were injected IM with 50 mg/kg of native ABC or an
equivalent ABC dose as NMABC or FA-NMABC. Mice have approximately 10fold higher free folate levels than humans, and excess folate may block the
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FOLR and interfere with rapid uptake of FA-targeted nanoformulation [35]. Thus,
prior to treatment, mice were placed on folate-deficient diet for 2 weeks to reduce
plasma folate levels [18]. For ABC and MABC analysis, whole blood was
collected immediately into acetonitrile to inhibit the activity of esterases, which
would cleave the myristoyl group from MABC, and adenosine deaminase, which
could convert ABC to carbovir [30]. ABC blood levels measured at days 1, 3, 5,
7, 9, 12, and 14 post treatments were significantly higher in mice treated with FANMABC compared to those treated with NMABC or native ABC. MABC was
lower than the limit of quantitation (< 0.125 ng/ml) in all samples, indicating rapid
conversion of the MABC to ABC in blood. By day 14, ABC blood levels were 36 ±
4.7ng/ml, 21 ± 3.8 ng/ml, and below the limit of quantitation (0.5 ng/ml) in mice
treated with FA-NMABC, NMABC and native drug, respectively (Figure 4.9).
4.4. DISCUSSION
Currently,

the

nucleoside

reverse

transcriptase

inhibitor

ABC

is

recommended as a component of a first line treatment regimen by the National
AIDS Control Organization [36]. In combination with two other NRTIs, for
example, zidovudine and lamivudine (3TC) such as Trizivir, it is part of a threedrug antiretroviral regimen [36, 37]. Notably, viral strains that are resistant to
zidovudine or 3TC can be sensitive to ABC [38]. However, ABC is associated
with a dose dependent hypersensitivity response that may lead to death if
therapy is not discontinued, and patients must be pre-screened for the HLAB*5701 allele [39]. ABC can be used as an alternative to Truvada in preexposure prophylaxis (PrEP) drug regimens used in the management of HIV-1
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transmission [40, 41]. Trizivir and other combination therapies lead to decreased
viral resistance and improved long-term survival. Currently, ABC, 3TC, and
dolutegravir are recommended as the most effective ART regimen [42]. However,
the short half-lives of the current regimens and the intrinsic physicochemical
properties of these antiretroviral drugs have limited their utilities and hence
demonstrate the need for long acting delivery platforms that can improve patient
adherence and facilitate drug entry into restricted anatomical reservoirs of HIV-1
persistence [15]. While progress has occurred towards developing long acting
nanoformulations for protease and non-nucleoside RT inhibitors [16, 19, 20, 43]
development of nanoformulations of hydrophilic drugs has remained elusive.
Attempts have been made to encapsulate ABC into polymeric nanomedicines but
poor loading and fast release kinetics have hampered their clinical applicability
[44].
To overcome such challenges, a carboxylic acid ester prodrug approach
has been widely used to improve lipophilicity and oral absorption of nucleoside
analogs [23, 45]. In this approach, a carboxylic acid containing hydrophobic alkyl
chain is reacted with the hydroxyl group located at the five membered ring moiety
of the nucleoside analog. Even though the carboxylic acid ester prodrug
approach has been used to modify a variety of anticancer compounds [46, 47]
and antiviral drugs [48], development and nanoformulation of hydrophobic
derivatives of antiretroviral drugs such as 3TC and ABC remain elusive. The goal
of the present study was to improve the half-life and therapeutic efficacy of ABC
through derivatization of the highly water soluble parent drug with a hydrophobic
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fatty acid side chain to generate a myristoylated prodrug that would be easily
encapsulated

into

polymer

excipients

and

other

surfactants

to

target

macrophages. The 5-hydroxyl group on the cyclopentene moiety of ABC was
esterified with myristic acid, a 14 carbon chain fatty acid. MABC was successfully
synthesized at a final yield of 66% after purification and characterized using 1HNMR and FTIR spectroscopy. In the cell, MABC was converted to ABC by
esterase cleavage followed by phosphorylation to produce the therapeutically
active compound [30]. The success of such a strategy has been shown for CP4126, a fatty acid prodrug of gemcitabine, which upon cleavage by esterases
resulted in a 200-fold increase in therapeutic activity [46]. Our results
demonstrated that prodrug synthesis does not impair the antiretroviral activity of
parent ABC, as determined by RT activity.
Over the past decade, work from our laboratory has demonstrated the
potential of targeted nanoART to produce sustained high plasma and tissue drug
concentrations for weeks following a single IM administration that can suppress
ongoing viral replication and mitigate dose associated viral resistance [17, 19]. In
this context, nanoART was manufactured using folate-conjugated P407 that
targets the FOLR2 expressed on activated macrophages [20]. Macrophage
activation and subsequent overexpression of FOLR2 can be induced by folateconjugated therapeutics [49]. Our results demonstrated that P407 and FA-P407
coating of MABC produced stable nanoformulations of similar physicochemical
parameters. The drug loadings for both nanoformulations were high (62-65%
w/w), which offers the advantage of administering a dose with less non-active
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excipients. Since the geometry of nanoparticles plays an important role in
determining attachment to the macrophage surface [50], the morphology of the
MABC nanoformulations was analyzed using SEM. Our results demonstrated
that the morphology for both NMABC and FA-NMABC nanoparticles was
cylindrical rods, which is advantageous in terms of macrophages uptake. The
mechanism reflects the preference of macrophages for engulfment of most
bacteria that have a rod shaped geometry in nature [51].
In the case of folate targeting, receptor-mediated endocytosis occurs
through interaction of folic acid moieties present on FA-nanoART with FOLR
present on the macrophage surface [20]. Our results demonstrated that FANMABC nanoformulations showed a significantly increased macrophage uptake
through binding to the FOLR compared to non-targeted NMABC. Indeed, folatemediated uptake was cross validated by the inhibition of FA-NMABC uptake by
blocking the FOLR with excess free folic acid (Figure 4A). When FOLR were
blocked, the uptake of FA-NMABC by MDM was significantly decreased to a
level similar to that for NMABC demonstrating that the superior uptake of folate
nanoformulations occurred through engagement of the FOLR. Consequently, the
amount of MABC that was retained in MDM using FA-NMABC was greater
compared to that for NMABC nanoformulations (Figure 4B). MDM retained more
than 2-fold greater levels of FA-NMABC than NMABC over a period of 15 days.
As a consequence of enhanced uptake and retention of MABC, the FA-NMABC
nanoformulations exhibited superior antiretroviral activity compared to NMABC
nanoformulations as measured by RT activity and HIV-1 p24 antigen staining
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(Figure 4C & D). The protection of MDM from HIV-1ADA infection was observed
for 15 days using folate-targeted nanoformulations, in contrast to reduction in
protection by 5-10 days for non-targeted formulations and free drug. Thus,
sustained drug delivery and improved antiretroviral activity of MABC might be
expected in vivo using folate-coated nanoformulations. In addition, no cytotoxicity
was observed in MDM at the nanoformulations concentration tested.
Our laboratory demonstrated previously that storage of nanoART in late or
recycling endosomal compartments provides a protected environment for the
encased cargo in the same subcellular organelles that harbors the pathogen and
promotes slow release of the encapsulated drugs. Similar subcellular trafficking
pathways for nanoparticles and HIV would enhance the antiretroviral response of
the

drugs

[32,

52].

In

this

study,

subcellular

localization

of

MABC

nanoformulations was investigated in MDM. Our results showed greater colocalization of the MABC nanoformulations in recycling endosomal compartments
(Rab11 and Rab14) compared to late endosomes (Rab7) or lysosomes (LAMP1)
(Figure 5). For each compartment, the uptake of folate-targeted nanoformulation
was significantly higher compared to non-targeted nanoformulation. These
results reflect the higher overall uptake and greater antiviral efficacy of FANMABC compared to NMABC. However, some nanoparticles were localized in
the degrading lysosomal compartments. Therefore, future studies will focus on
minimizing

the

amount

of

nanoparticles

trafficked

into

compartments to further improve the antiretroviral outcomes.

the

lysosomal
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To determine whether FA-NMABC compared to NMABC or free drug
could provide sustained blood drug levels, mice were treated with 50 mg/kg of
ABC as free drug or MABC nanoformulations. Blood drug levels of ABC were
detectable over 14 days following treatment with nanoformulated MABC. The
folate coating increased the blood levels of ABC by approximately 2.5-fold
compared to non-coated formulations and up to 18-fold compared to native drug.
Interestingly, no MABC was detected in the blood of mice treated with MABC
nanoformulations. This suggests that following release from the nanoformulation,
MABC was efficiently converted to ABC by blood and tissue esterases. Hence,
folate coating of nanoformulated crystalline MABC could be an effective strategy
to reduce HIV levels in its sanctuaries by maintaining sustained blood drug
levels.
4.5. CONCLUSIONS
We demonstrate that a carboxylic acid ester prodrug of ABC has improved
antiretroviral activities over the native hydrophilic compound. The improved
lipophilicity

facilitated

the

encasement

of

the

prodrug

into

poloxamer

nanoformulations with high drug loading. Notably, coating the prodrug with a
folate-modified

polymer

directed

to

the

folic

acid

receptor

enhanced

nanoformulation uptake, retention, and antiretroviral efficacy of the drug. MABC
nanoformulations

localized

to

recycling

endosomal

compartments

in

macrophages, as previously observed for nanoformulated atazanavir and
ritonavir [32]. Of importance, following a single IM injection, blood concentrations
of ABC were maintained over 14 days using decorated nanoformulations.
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4.6. SUMMARY
4.6.1. MABC Synthesis


Modified ABC (MABC) was synthesized by esterification of myristic acid to
the 5-hydroxyl- cyclopentene moiety of the drug.



MABC was recovered with 66% efficiency after purification.



When compared to ABC, the antiretroviral activity of MABC, was
increased 2–fold in MDM.

4.6.2. Synthesis of MABC Encased Nanoformulations


MABC was readily incorporated into P407 (NMABC) nanoparticles with a
size range of 150-200 nm and a monodispersed cylindrical morphology.



The nanoformulations were stable at 4 °C and 25 °C for at least 8 weeks.

4.6.3. PK Evaluation of MABC Nanoformulations


Folate-targeting of the nanoformulation facilitated human MDM uptake and
retention, and improved antiretroviral efficacy when compared to NMABC
and free MABC.



Macrophage drug depots were localized in recycling endosomes (Rab11
and Rab14).



Following a single IM injection of NMABC or FA-NMABC in mice, blood
concentrations of ABC were maintained over 14 days.



FA-NMABC enhanced blood drug levels in mice by 1.7-fold compared to
non-targeted nanoformulation (NMABC).
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Figure 4.1. Synthesis of MABC. MABC was synthesized as illustrated at a final
yield of 66%. The synthesis of MABC was accomplished through derivatization of
the native compound with a cleavable fatty acid ester in four steps; (1) The
hydroxyl and amino groups of ABC were protected using TBSCl, and DMTr-Cl
respectively, (2, 3) the TBSCl groupd was selectively removed, followed by
selective coupling of myristoyl chloride at 5-OH position of ABC, finally, (4) the
DMTr-Cl protecting group was removed using TFA to yield final product. MABC
was purified using silica chromatography.
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Figure 4.2. Characterization of MABC. Covalent linkage of myristic acid to the
5’-O-hydroxyl group of ABC was confirmed by nuclear agnetic resonance,
Fourier transform infrared spectroscopy and tandem mass spectrometry ( 1HNMR, FTIR and MS/MS); (A) The 1H-NMR spectrum of MABC showed the
presence of an intense broad peak at 1.21-1.50 ppm. This peak corresponds to
the aliphatic protons on the fatty acid moiety. (B) Peaks at 2915 cm-1 and 2850
cm-1 in MABC FTIR spectrum correspond to alkane (CH2-CH2) stretching of the
myrisitic acid alkane.
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Figure 4.3. Antiviral activity of ABC and MABC in HIV-1ADA infected MDM.
MDM were treated with various concentrations of ABC or MABC for 60 min and
then challenged with HIV-1ADA at a multiplicity of infection of 0.01 infectious viral
particles/cell for 4 h. The cells were incubated for a further 10 days with MCSFfree media containing the same drug concentration. HIV RT activity was
measured in the infectious supernatant on day 10 post-infection.
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Figure 4.4. Morphology and stability of NMABC. SEM images of (A) NMABC
and (B) FA-NMABC nanoformulations. Both formulations appeared as cylindrical
monodispersed particles of ~200 nm. Stability of the NMABC nanoformulation
was assessed by measuring (C) particle size and (D) PDI at 4 °C and 25 °C for 8
weeks.
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Figure 4.5.Characterization of nanoformulated MABC using 1H-NMR
spectroscopy. The 1H-NMR spectrum of NMABC showed the presence of a
singlet at 3.7 ppm that corresponds to the methylene-repeating unit of the
polymer. Peaks corresponding to the myristoylated prodrug protons are also
displayed on the formulation spectrum.
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Figure 4.6. MDM uptake and retention of NMABC and FA-NMABC. (A) MDM
uptake of 100 µM NMABC or FA-NMABC was determined over 8 h. For uptake
studies, 50 µM free folic acid (FA) was added to MDM prior to treatment with FANMABC to block FOLR binding. (B) MDM retention of NMABC or FA-NMABC
was determined over 15 days. For uptake studies, statistical differences were
determined using one-way ANOVA among three groups; for retention studies
statistical differences were determined using Student’s t-test (**P < 0.001 and *P
< 0.05).
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Figure 4.7. Antiretroviral activity of NMABC and FA-NMABC measured in
MDM. Antiretroviral activity was determined in MDM treated for 8 h with 100 µM
free MABC or nanoformulated MABC and then infected with HIV-1ADA at 1, 5, 10
or 15 days following drug loading. HIV replication was determined 10 days after
infection by (A) HIV RT activity and (B) HIV p24 staining.
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Figure 4.8. Subcellular localization of nanoformulated MABC in MDM. MDM
cultured in 8 well Lab-Tek II CC2 chamber slides were treated with 100 μM
CF633-labeled FA-NMABC or CF633-labeled NMABC for 8 h then fixed and
stained with antibodies to Rab7, -11, -14, and LAMP1 as described [20]. (A) Colocalization is observed as a yellow punctate pattern throughout the cytoplasm
and perinuclear cell regions in merged images of red nanoparticles and green
subcellular compartments. (B) Percent fluorescence overlap was quantitated
using ImageJ software, and JACoP plug-in. Statistical differences were
determined using Student’s t-test (*P < 0.05).
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Figure 4.9. Plasma and tissue drug levels of nanoformulated MABC in mice.
Balb/c mice were administered intramuscularly 50 mg /kg equivalents of ABC
using free ABC, NMABC or FA-NMABC on day 0 and sacrificed on day 14.
Whole blood was collected into acetonitrile for drug analysis on days 1, 3, 5, 7, 9,
12, and 14 after treatment. ABC levels were determined by UPLC-MS/MS. Data
are expressed as mean ± standard error of mean. *** (P < 0.0001), *(P < 0.05)
statistically different from ABC as determined by 2-way ANOVA and Bonferroni’s
Multiple Comparison tests
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Chapter 5
Challenges and Future direction
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Even though the prodrugs synthesis, followed by its encapsulation into
long acting PLGA and pluronic nanoformulations showed considerable
improvement over poor efficacy and PK/PD profile of native drug, pitfall exists.
Firstly, the manufacturing scheme was not optimized to clinical translation;
moreover it was design for proof of concept studies. There is further need to
generate more robust manufacturing process that generates particles with
homogeneous physicochemical parameters. For instance, in current methods,
purification of nanoformulation using centrifugation led to particles aggregation
that poses a major challenge in resuspending the particles with initial size and
size distribution. Secondly, robust lyophilization methods need to develop, if we
chose to develop powder formulation for longer stability.
Therefore, future work should employ other alternative purification
techniques such as tangential flow filtration (TFF) to circumvent the aggregation
problem associated with conventional centrifugation. TFF is an efficient method
of purification using membrane filtration to isolate nanoparticle and free
polymers, and/or unencapsulated drugs.
The scope of this research limited to develop two separate prodrugs;
phosphorylated pro-drug to bypass inefficient monophosphorylation conversion,
and myristoylated prodrugs to improve hydrophobicity that encourages its
encapsulation in to long acting nanoformulations. The probabilities of developing
phosphorylated prodrugs with fatty acid end chain that pose improve
phosphorylation and hydrophobicity concomitantly should be tested in future.
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We can improve the PK of our nanoformulated MABC using a range of
particle surface ligands or through the use of mixed lineage kinase inhibitors that
can affect autophagy and prolong the nanoparticle storage capacities. If
successful, this would improve antiretroviral activities and facilitate MABC’s use
as a component in a long-acting ART regimen. Such strategies are now being
tested in relevant mouse models of HIV/AIDS. Parallel development of a
nanoformulated hydrophobic prodrug of 3TC would provide a combination drug
regimen with MABC and a long-acting formulation of the integrase inhibitor
dolutegravir. Future development of a combination long acting prodrug-based
delivery system would be a considerable benefit in the management of HIV
infection.

